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 ABSTRACT  
Background  
Glaucoma is a major cause of irreversible blindness in Africa due to its high prevalence, 
early age of onset and aggressive course. Patients often present very late and have poor 
awareness and limited access to services with limited treatment options to lower the 
intraocular pressure. When treatment is available there is often poor acceptance of 
surgery, the preferred treatment in Africa. To prevent blindness from glaucoma a 
behaviour change intervention is required to increase awareness and encourage 
acceptance of and adherence to treatment and follow up. Motivational interviewing (MI) 
was selected and adapted for this study as it has shown promise in adherence to 
treatment in other chronic diseases, and non professional counsellors can be trained to 
deliver it. To improve treatment options transscleral diode laser cyclophotoablation was 
introduced before the trial started 
 
Methods 
Design: single site pragmatic randomized controlled trial with 1:1 allocation to one 
session of MI or enhanced usual care. MI was adapted for the local context and language 
was carried out using an interview guide generated following qualitative research. 
Participants allocated to MI were randomly allocated to one of two interviewers. Usual 
care was routine explanation by an ophthalmologist and an educational pamphlet. After 
the interview, a 12-item Working Alliance Inventory short questionnaire was 
administered to patients and interviewers to assess the collaborative relationship. The 
primary outcome of the trial was the proportion of participants who accepted and 
underwent surgery or laser treatment within two months of the date given. Laser 
treatment was performed using diode 810nm laser G-probes under retrobulbar 
anaesthesia and standard procedures. Patients were reviewed on day one, one week and 
at 1, 4, 6 and 12 months when IOP and visual acuity were measured.  
 
Results 
276 patients participated in the trial: 135 (49%) were assigned to MI and 141 to usual care. 
53% of patients in the MI group underwent treatment compared with 45% in the usual 
care group (risk ratio 1.2; 95% confidence interval (CI) 0.9-1.6). Overall acceptance was 
49% higher than before the trial. Analysis of WAI scores showed similar scores for 
participants and interviewers overall. Interviewer and participant scores had high 
reliability coefficients (94.3% and 93.3% respectively) with good correlation when 
combined using Cronbach's alpha (93.9%). In the laser treatment study, data from 204 
eyes treated were included in the study. Before treatment mean IOP was 39mmHg being 12, 
11, 15, 18, 19 and 19mmHg on day one, at one week, and 1, 4, 6 and 12 months respectively. At 
12 months 77 (72.6%) eyes (106/107 with data) had IOPs <22mmHg. At 12 months 83 (78%) eyes 
retained (70 eyes, 66%) or had improved (13 eyes, 12%) visual acuity; 25 eyes (23%) lost acuity. 17 
eyes were retreated. No eyes had persistent hypotony. 
 
Conclusion 
The results do not support the introduction of this adapted MI tool to increase 
acceptance of glaucoma surgery in Africa as we observed only a small increase in 
acceptance compared with usual care, which was not statistically significant. Although 
only 1 in 2 patients accepted surgery or laser in this trial this is a much higher proportion 
than observed in other studies. In this trial the majority of participants underwent laser 
treatment, which is less invasive, repeatable and cheaper than trabeculectomy.  The 
diode laser treatment appears to be a good alternative to surgery in this setting as it is 
acceptable, gives good IOP control and good preservation of vision at one year. Trials of 
different modalities of laser as a primary treatment for glaucoma in Africa are warranted. 
 
 
 
 
 
 
 
 
 
 
 
 PREFACE (format of the thesis) 
The thesis for this PhD uses the “research/review paper” format that was recently 
introduced by the London School of Hygiene & Tropical Medicine. It therefore includes a 
number of papers, which have been published or are formatted for submission to peer-
reviewed journals. The chapters listed in the Contents page are formatted this way and 
include publication details in a cover sheet, which includes acknowledgement of the 
contributions of other people I worked with. Information and data that make the body of 
the thesis more coherent and not presented or covered in the papers is included as 
“linking material” in other chapters. I, Mohammed M Abdull, wrote the linking material. 
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INTRODUCTION 
How ideas for the thesis developed 
As an ophthalmologist working in Africa, I was frustrated that when it came to managing 
glaucoma patients we seemed to be making no progress at all. I noticed that many of my 
patients were not aware of the seriousness of their condition, and did not understand the 
rationale for continued adherence to medication. I was concerned to hear from my 
patients that they had not been using their medication regularly, so that it was not 
possible at follow up to know whether uncontrolled IOP was due to medical treatment 
failure or simply poor adherence. To avoid this vicious cycle of poor adherence we often 
advise early surgery which patients usually refuse, as they do not understand why 
surgery is needed for a seeing eye and not for a blind eye (as with cataract).  
 
My interest in glaucoma was further increased after seeing the results from the Nigeria 
blindness and low vision survey. Concern for my patients informed my decision to try 
and find a solution to increase acceptance of early surgery and to improve adherence to 
medication and follow up to prevent needless blindness in patients often are often in 
their prime. My reading of the literature suggested that this goal could be achieved by an 
increasing treatment options and by improving patient’s awareness. This concern formed 
the basis of this study. 
 
The following chapter describes the epidemiology of glaucoma in Africa. The table in the 
chapter summarises the prevalence and the proportion of blindness caused by glaucoma 
in various African population. Data were sourced from a comprehensive review of large 
population and hospital based surveys. 
 
 
 
 
 
 
 
 
 
 
The structure of the rest of the thesis 
Chapter 1. Describes glaucoma epidemiology and risk factors in Africa. These papers 
were written with colleagues also working on glaucoma and jointly carried out reviews of 
published data on glaucoma in Africa.  There are 3 published papers included in the 
chapter. The first is a review of the epidemiology of glaucoma in sub-Saharan Africa. The 
second is an analysis of risk factors for glaucoma in Africa from the results of the 
National Blindness and Low Vision Survey (NBS). The NBS was the largest prevalence 
study of blindness and low vision carried out in Africa and field work was undertaken 
between 2004- 2007. I was part of the team that carried out the survey and collected the 
data. As the survey was designed to cover more than 500 million people who share the 
same ecological zones in west, central and eastern Africa, the findings may apply to a 
much larger population. The third paper is another review of posterior segment eye 
diseases in Africa. 
 
Chapter 2. This describes the challenges that glaucoma poses in Africa. It starts with a 
review of the unique challenges faced by both patients and ophthalmologists in 
managing glaucoma. It reviews the outcome of surgical treatment for glaucoma in 
African patients and also discusses health education and different approaches to 
increasing awareness and knowledge of glaucoma to overcome some of the challenges. 
Motivational interviewing (MI) is introduced and the rationale for using it in this study 
to address the problem of poor acceptance of surgery. There are two published papers in 
this chapter. The first illustrates the late presentation of glaucoma and very poor 
acceptance of treatment among patients presenting to the eye department where I work 
in northern Nigeria. The second introduces glaucoma as the “silent thief of sight” and 
describes glaucoma from the patients’ perspectives and explores their health seeking 
behaviour 
 
Chapter 3 describes MI in more detail and its use in managing adherence to treatment in 
other conditions. The paper in this chapter is a narrative submitted for publication of our 
effort in learning MI and the challenges we faced in a non-western society. 
 
Chapter 4 is a general description of the context of the study and describes the study 
location. Papers included in this chapter give a background of the usual care for 
glaucoma in the study location and describe a case study of a typical glaucoma patient in 
Nigeria with suggestions on how to manage such patients. The last two papers describe 
the general medical care of glaucoma patients and how to manage the patient after 
glaucoma surgery in the setting. 
 
Chapter 5 describes the clinical trial along with the rationale, aims and objectives and a 
detailed methodology. The study protocol of the trial forms the first published paper in 
the chapter while the second is an educational poster produced for patient education. 
 
Chapter 6 describes the primary outcome of the clinical trial in a published paper. 
 
Chapter 7 introduces a new intervention, transcleral diode laser cyclophotocoagulation 
(TDLC), in an attempt to increase the options available for patients to treat glaucoma in 
Africa. It describes TDLC, the rationale for using it and a brief review of diode lasers in 
Africa. The paper describes the results from a cohort of patients treated with cyclodiode 
and followed up for one year. 
 
 
Chapter 8 describes the implications of the findings of my work for practice, policy and 
further research. It discusses what next as the primary outcome of the trial failed to 
prove the hypothesis.
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Chapter 1. Glaucoma in Africa: Epidemiology, 
Description of glaucoma and definitions  
The following chapter describes the epidemiology of glaucoma in Africa. The table in the 
chapter summarises the prevalence and the proportion of blindness caused by glaucoma 
in various African population. Data were sourced from a comprehensive review of large 
population and hospital based surveys. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A typical blind glaucoma patient being led to the eye clinic by his son in 
Bauchi, Nigeria,  
 
Figure 2: Optic disc photos. On the left, glaucomatous optic atrophy, and normal 
optic disc on the right 
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Glaucoma 
Glaucoma is a group of acquired conditions characterised by optic neuropathy and 
typical patterns of visual field loss in more advanced stages.[1] In the public health 
context, glaucoma is an optic neuropathy associated with characteristic structural 
damage to the optic nerve and associated visual dysfunction that may be caused by 
various pathological processes.[2] The glaucomas can be classified based on the 
underlying abnormality that causes raised intraocular pressure (IOP) into primary open 
angle glaucomas (POAG), angle closure glaucomas, and glaucomas associated with 
developmental anomalies.[3] Glaucoma can be primary or secondary to other ocular 
conditions such as ocular trauma, neovascularisation, uveitis, drugs (e.g. steroids), 
diabetes mellitus and complicated or intumescent cataract. 
 
Epidemiology of glaucoma 
Glaucoma causes irreversible blindness in 4.6 to 6.7 million people worldwide. [4, 5] [4, 
5] The number of people with glaucoma was estimated to be 60.5 million in 2010, which 
will increase to almost 80 million by 2020. [6] 
 
Data from the national blindness and low vision survey in Nigeria revealed the 
prevalence of blindness in all ages to be 0.78%. 16.3% of this blindness was due to 
glaucoma, which was the 2nd commonest cause after cataract.[7] The prevalence and 
proportion of blindness caused by glaucoma from various studies in Africa or people of 
African origin is summarised in table 1 
 
Risk factors for glaucoma  
High Intraocular pressure 
Risk factors for glaucoma include raised IOP, increased age, African Caribbean origin, 
and family history of glaucoma.[8] The risk of glaucomatous optic nerve damage 
increases with the height of the screening IOP. Results in the Baltimore eye survey 
confirmed that IOP is an important factor in glaucoma.[9] 
 
 
Family history 
Primary open angle glaucoma (POAG) has been shown to be familial. The relative risk of 
developing glaucoma in the Rotterdam study was 9.2 for individuals with a family history 
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of glaucoma.[10] In a Tasmanian study, adjusted analysis revealed that a family history of 
glaucoma in first-degree relatives (FDRs) and IOP of >21 mm Hg were significantly 
associated with glaucoma and showed that for a person with POAG the odds ratio of 
having a positive family history was 4.1 (95% confidence interval: 3.2–5.2). [11] 
 
Other Risk Factors 
There are other risk factors that have been observed. The Los Angeles Latino study 
revealed that older age, male gender, unmarried marital status, and being a first-degree 
relative were independent risk factors for OAG.[12] Others at risk are myopes,[13] 
diabetics and black people aged 40 years and above,[14] etc. Risk factors from the Nigeria 
national blindness survey include high IOP, increasing age and Igbo ethnicity as 
independent risk factors. Others were low BMI, severe hypertension, long axial length 
and illiteracy.[15] Individuals of African descent have thinner corneas[16] and IOP may 
be underestimated in blacks because of thinner corneas.[17] They also have greater optic 
disc area and cup depth than Europeans.[18] 
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Table 1. Prevalence or proportion of blindness caused by glaucoma in different African populations 
 Study/ref Year Place of study Study type Age 
range(y
ears) 
POAG 
prevale
nce (%) 
blindness by 
POAG (%) 
Number 
examined 
Remarks 
1. 2 Buhrmann. 
[19] 
2000 Kongwa, 
Tanzania 
Pop based ≥40 3.08   3247   
2. 3 Rotchford. 
[20] 
2002 Kwazulu Natal, 
S/Africa 
Pop based ≥40 2.7 22 1005   
3. 7 Rotchford. 
[21] 
2003 Temba, S/Africa Pop based ≥40 2.9   839 87% not previously 
diagnosed 
4. 2
9 
Tielsch JM et 
al. [22] 
1991 Bailtimore USA Pop based ≥40 blacks 
4.74 
whites 
1.29 
  2395 
2913 
 Glaucoma 4-5 times 
higher in blacks 
5. 3
0 
Quigley HA 
et al. [23] 
2001 Arizona, US Pop based ≥40   1.97 4774  37% of POAG cases not 
aware they had it before 
the study. Gender, BP, 
smoking not risk factors 
6. 3
3 
Sommer A et 
al. [24] 
1991 Bailtimore, USA Pop based ≥40   Blacks 19 2395   
7. 3
4 
Abdull MM 
et al. [7] 
2009 Nigeria Pop based ≥40 0.7% 16.7 13,599  
8. 3
6 
Melese, M.et 
al. [25] 
2003 Central Ethiopia Pop based ≥40  Blindness 7.0% 
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The following papers review the epidemiology of glaucoma in sub-saharan Africa and 
discuss evidence regarding risk factors for the onset and progression of glaucoma and 
risk factors for glaucoma blindness. Three papers follow. These are: 
1. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk 
factors. Kyari F, Abdull MM, Bastawrous A, Gilbert CE, Faal H. Middle East Afr J 
Ophthalmol. 2013;20(2):111-25. 
2. Risk factors for open-angle glaucoma in Nigeria: results from the Nigeria 
National Blindness and Visual Impairment Survey Kyari F, Abdull MM, Wormald 
R, Evans JR, Nolan W, Murthy GV, et al.. BMC Ophthalmol. 2016;16:78. 
3. Posterior segment eye disease in sub-Saharan Africa: review of recent population-
based studies. Bastawrous A, Burgess PI, Mahdi AM, Kyari F, Burton MJ, Kuper 
H.. Trop Med Int Health. 2014. 
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Paper 1: Epidemiology of glaucoma in sub Saharan Africa: 
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Posterior segment eye disease in sub-Saharan Africa: review
of recent population-based studies
Andrew Bastawrous1, Philip I. Burgess2, Abdull M. Mahdi1,3, Fatima Kyari1,4, Matthew J. Burton1,5 and
Hannah Kuper1,6
1 International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK
2 Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital, Blantyre, Malawi
3 Department of Ophthalmology, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria
4 Department of Ophthalmology, College of Health Sciences, University of Abuja, Abuja, Nigeria
5 Moorfields Eye Hospital, London, UK
6 International Centre for Evidence in Disability, London School of Hygiene & Tropical Medicine, London, UK
Abstract objective To assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
methods We reviewed published population-based data from SSA and other relevant populations
on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular
degeneration, as causes of blindness and visual impairment in adults. Data were extracted from
population-based studies conducted in SSA and elsewhere where relevant.
results PSEDs, when grouped or as individual diseases, are a major contributor to blindness and
visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness
after cataract, ranging as a proportion of blindness from 13 to 37%.
conclusions PSEDs are likely to grow in importance as causes of visual impairment and blindness
in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-
based cohort studies are required to help estimate present and future needs and plan services to
prevent avoidable blindness.
keywords glaucoma, diabetic retinopathy, age-related macular degeneration, posterior segment eye
disease, prevalence, incidence, blindness, visual impairment, Africa
Introduction
Non-communicable diseases in low- and middle-income
countries
In recent decades, there has been a marked rise in life
expectancy that has contributed to a major epidemiologi-
cal shift in populations worldwide (Lopez et al. 2006).
These changes will increasingly lead to major public
health issues in low- and middle-income countries
(LMIC; Mathers & Loncar 2006). Current projections
suggest that non-communicable diseases (NCDs) will con-
tribute to two-thirds of global mortality by the year 2030
(Mathers & Loncar 2006). NCDs in LMIC have shown
substantial variation in prevalence, incidence, natural
history and risk factors compared with NCDs in popula-
tions in high-income countries (Boutayeb 2006).
Visual impairment and blindness
285 million people are visually impaired (VI) worldwide,
(severe visual impairment (SVI) defined as presenting
visual acuity (PVA) <6/60 but ≥3/60, moderate VI defined
as PVA <6/18 but ≥6/60) of whom 39 million are blind
(presenting visual acuity <3/60 in the better eye; Pascolini
& Mariotti 2012). Approximately 90% of those world-
wide with VI live in low-income countries. NCDs are the
leading causes of VI, in part due to the successful control
of infectious diseases. VI is ranked sixth in the top ten
causes of burden of disease in terms of disability-adjusted
life-years (DALYs) in low-income, middle-income and
high-income countries (Chiang et al. 2006). The sum of
DALYs from VI is 66 290 000 (4.3% of total), just
below HIV/AIDS at 71 460 000 (4.7%).
The number of people visually impaired in the World
Health Organization (WHO) African region is estimated
to be 26 million, of whom almost 6 million are blind.
This is based on estimates from population-based studies
in Botswana, Cameroon, Eritrea, Ethiopia, Gambia,
Ghana, Kenya, Mali, Nigeria, Rwanda, Uganda and Tan-
zania (Pascolini & Mariotti 2012). Despite Africa having
one of the highest prevalences of blindness, it is the most
underserved continent in terms of human resources
© 2014 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd. 1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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Chapter 2: Management of glaucoma and challenges in 
management in Africa 
Challenges of glaucoma treatment and outcomes in Africa  
Glaucoma treatment 
Of all the risk factors for glaucoma, the only modifiable risk factor is IOP. Lowering the 
IOP has been associated with reduced progression of visual field defects. [55] Many 
different treatments exist and most aim to reduce IOP. These options are: topical or 
systemic medication; surgery, which involves creating a fistula to increase outflow of 
aqueous humour; Laser treatment used to either decrease the production of aqueous or 
increase the outflow facility. Some other medications such as Memantine do not lower 
IOP but may provide some neuroprotection to the optic nerve though there is lack of 
compelling medical evidence.[56, 57] Blacks are less responsive to both medical and 
surgical treatment for POAG.[58] 
 
Medical treatment  
The medical treatment options use different classes of drugs, which include:  
prostaglandin analogues, such as latanoprost; Beta-blockers such as Timolol; carbonic 
anhydrase inhibitors which can be oral e.g. acetazolamide or topical e.g. brinzolamide 
and dorzolamide; alpha-adrenergic agonists such as Brimonidine; sympathomimetics 
such as Epinephrine; parasympathomimetics, such as Pilocarpine; and hyperosmotic 
agents such as mannitol. Drugs can be used in combination. New treatments 
under investigation include Punctal Plug Delivery Systems and use of nanoparticles for 
drug delivery. 
 
Topical ocular hypotensives are the most frequently used and are effective not just in 
treating high IOP, but in delaying or preventing the onset of POAG in African American 
individuals who have ocular hypertension.[59] Studies in blacks show that Bimatoprost 
achieved slightly more clinically relevant IOP reductions than Travoprost, [60] or that 
there is no difference between whites and blacks [61] though there is a higher post-
treatment inter-visit IOP range in African-Americans.[62] In another study there was no 
difference in IOP response to non-selective beta-adrenergic antagonists between African 
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American and white participants, but responses to prostaglandin analogues was slightly 
greater in African American though the difference was not statistically significant.[63] 
Whatever type of medicine is prescribed, it is important that patients are given the 
correct prescription and obtain the drug prescribed, store it in an ideal environment, use 
the drugs as prescribed at their right times and continue to do so as instructed. Storage 
of medications could also be a problem in warm climates, but a study of Latanoprost 
stored at 300C for four weeks after opening the bottle remained as effective and safe as 
that stored under cold conditions.[64] 
 
Surgical treatment 
The surgical options are trabeculectomy with or without [65] antimetabolites like 
Mitomycin C and 5-Fluorouracil which are used where the risk of failure due to excessive 
scarring is high. Other surgical procedures are trabeculotomy, goniotomy and drainage 
implant surgery, and non-penetrating surgeries such as canaloplasty and new minimally 
invasive surgical techniques.  
Trabeculectomy is the operation of choice in African populations [65-67] where it offers 
good IOP control in 70-80% of patients (Table 2). Trabeculectomy has a higher risk of 
bleb failure in blacks from excessive scarring than in Caucasians eyes. The risk of failure 
is high especially if no antimetabolites are used. Therefore the use of antimetabolites is 
recommended as safe and effective in controlling IOP in many cases.[68, 69] 
Antimetabolites or anti-scarring agents e.g. 5-FU,[70] mitomycin C[69] and β 
radiation[71] have been employed to reduce surgical failure, but all are associated with 
complications such as hypotony and bleb infection. Other reasons have been proposed 
for the high failure risk of trabeculectomies in black populations, one being that black 
conjunctiva has more wound healing cells which promote scarring after surgery, [72] 
although this is not supported by convincing evidence.[73] The outcome of 
trabeculectomy in Africa is variable, offering good IOP control in 30-97% of patients. 
Table 2 shows the outcome of trabeculectomy in different African populations.  
 
Laser treatment.  
The laser treatments used include, Argon Laser Trabeculoplasty (ALT), Diode laser 
trabeculoplasty, (DLT) Selective Laser Trabeculoplasty (SLT) and cycloablation with 
either endo or transscleral diode laser cyclophotocoagulation and Nd-YAG 
cyclophotocoagulation 
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Laser trabeculoplasty increases outflow of aqueous and offers good short term IOP 
control. [74-77] An editorial on trabeculoplasty and trabeculectomy and race 
recommended that the first surgical intervention in patients with “advanced glaucoma” 
should be trabeculectomy in whites, and ALT in blacks. [78] Trabeculoplasty can also be 
performed using diode laser i.e. diode laser trabeculoplasty (DLT). Diode laser 
trabeculoplasty and ALT are equally effective in lowering IOP in eyes with uncontrolled 
glaucoma on maximally tolerated medical treatment. [75] 
Cyclodestruction has been in use for refractory glaucoma especially for pain relief. 
Cyclodestruction is usually carried out with the diode or Nd-YAG lasers through the 
sclera or under direct vision combined with cataract surgery 
(endocyclophotocoagulation). Trans scleral diode laser cyclophotocoagulation is 
receiving increasing support not only for eyes with refractory glaucoma but also those 
with uncontrolled IOP with residual good vision. [79-82] The procedure is minimally 
invasive and can be carried out under local anaesthesia as a day case. There are some 
safety concerns however, most importantly hyphaema, choroidal detachment or long 
term hypotony. Table 3 below shows the outcome of diode laser cyclophotoablation in a 
range of studies while table 1B in chapter 7 also outlines the complications leading to 
decreased vision in many studies.  
 
Glaucoma treatment recommended in Africa 
Which treatment is given depends on several factors, e.g. stage of disease at 
presentation, the socio-economic and demographic features of the patient (level of 
awareness, family support, household economic situation, distance to health facility 
etc.), the resources available and the preference of the patient. A once-off treatment, 
surgery or laser, is probably the best option for advanced disease in many Africans, those 
who are poor and lack support, and where facilities for monitoring and follow up are 
lacking or the patient is not motivated. [83-85] Although surgery has been demonstrated 
to be the operation of choice, acceptance is poor in African patients,[86] mainly because 
of fear and the lack of visual improvement after the surgery. [84] Combined cataract and 
trabeculectomy has, therefore, been advocated for this reason in Africa, even if there are 
only minimal lens opacities, so that patients experience some improvement in their 
vision after surgery. [87] 
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Table 2.  Outcome of trabeculectomy in Africa 
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Table 3: Outcome of diode laser cyclophotocoagulation in Africa and other places 
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Acceptance, adherence to treatment and follow up 
Adherence to treatment for glaucoma  
 
A meta-analysis of observational studies showed that good adherence to drug therapy is 
associated with positive health outcomes.[122] The literature has many definitions for 
medication-taking behaviours. The common everyday interpretation of compliance is 
the passive following of doctors’ orders while adherence is the extent to which a person 
takes medication as prescribed by the doctor. Concordance is described as consultative 
and consensual partnership between the patient and their doctor, and persistence is the 
person’s ability to continue taking medications for the intended course of therapy as 
prescribed by the doctor. Many no longer accept the term compliance:   “The modern 
attitude to the word is that it betrays a paternalistic attitude towards the patient on the 
prescriber's part and that it should not be used”. (Aronson 2007 pp.383-384) [123] A more 
formal definition has been proposed that medication compliance may be defined as “the 
extent to which a patient acts in accordance with the prescribed interval and dose of a 
dosing regimen.” (Cramer, 2008 pp.45-46) Compliance is measured over a period of time 
and reported as a percentage, and medication persistence may be defined as “the 
duration of time from initiation to discontinuation of therapy” (Cramer, 2008 pp.45-46) 
[124] The World Health Organization (WHO) Adherence Project has adopted a 
definition of adherence to long-term therapy as the extent to which a person’s behaviour 
– taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider.[125] The National 
Coordinating Centre for the National Health Service (NHS) Service Delivery and 
Organization Research & Development (NCCSDO) reports adherence as the term of 
choice to describe a patient’s medicine taking behaviour. Adherence to treatment is a big 
problem not just in African or Black communities, but globally. The report also mentions 
that reviews conducted across disease states and countries are consistent in estimating 
that between 30-50% of prescribed medication is not taken as recommended.[126]  
 
Inadequate adherence with glaucoma eye drops is universal.[127] A recent review 
reported that up to 80% of glaucoma patients deviate from the regime prescribed. [128] 
[126] [127] Another study using an electronic dosing aid found significant differences for 
adherence rates between patients of European descent and those of African descent. 
Patients of African descent demonstrated poorer adherence for all three definitions used 
in the study.[129] Adherence to glaucoma medication is now receiving more attention in 
terms of risk factor studies as well as interventions to improve adherence [130-138] 
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including trials of patient education. [139] A Cochrane Systematic Review in 2009 
identified eight clinical trials designed to improve adherence with topical medication for 
glaucoma, none of which were undertaken in Africa. [136] Age is an inconsistent factor in 
adherence: in one study younger people were more likely to be non-adherent to 
glaucoma medication.[140] But it has been demonstrated that that older age was not a 
consistent risk factor for poor adherence to glaucoma medication.[141] 
 
Poor medication adherence has also been associated with visual field progression.[142, 
143]  Trust in physicians was slightly higher in whites than blacks but this was not 
associated with glaucoma medication adherence.[144] There are many recommendations 
to improve adherence to glaucoma treatment, including that physicians should 
incorporate adherence counselling broadly into their practices.[145] Many patients 
exhibits ‘white coat’ adherence in which patients’ adherence rises sharply one week 
before their appointment and then declines rapidly afterwards. This creates a decision 
dilemma for the ophthalmologist who may conclude that the particular regime is not 
adequate. This leads to unnecessary changing of eye drops or treatment options. An 
editorial on glaucoma medication adherence reports that proper adherence to a 
prescribed glaucoma medication regimen involves at least four steps: patients must 
obtain the medication; successfully instil the drop into the eye; use the medication at the 
appropriate time; and do so each day. These four steps have been conceptualized into 
two domains: the tasks of acquiring the medication and proper dosing and the more 
physical task of instilling a drop into the eye. [146] 
 
Patients are more likely to be adherent to treatment if they understand their disease, the 
rationale for treatment, and have a simplified treatment regime.[147] In a Finnish study, 
support from physicians and nurses, and being informed of the consequences of 
treatment was associated with greater adherence.[148] In-depth interviews conducted in 
glaucoma patients receiving treatment from two hospitals in Southeast United States 
showed that non adherent participants were less likely to believe their eye doctors spent 
sufficient time with them, ask their eye doctor if they had any questions, know the 
benefits of taking their glaucoma medication regularly, have someone help them take 
their glaucoma medications or drive them to eye appointments.[149] In a study to 
determine the extent of non adherence to treatment for glaucoma among elderly patient 
in a retrospective cohort study of 2440 patients older than age 65 who were enrolled in 
the New Jersey Medicaid Program, factors associated with non-adherence included the 
use of glaucoma medication requiring more than two administrations per day and the 
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presence of multiple other medications in the patient's drug regimen. Patients on 
multiple glaucoma medication were more adherent than those on a single agent and age 
and sex were not predictors of non-adherence.[150] In another US study of glaucoma 
patients starting treatment, nearly half had discontinued all topical ocular therapy 
within six months, which fell to 37% at three years.[151] Another study showed that 
patients prescribed once daily treatment were more likely to be adherent than those 
where a second medication had been added.[152] 
 
Literacy has often been associated with adherence to medication. For example, a study in 
the US showed that people with open angle glaucoma and low levels of literacy were less 
adherent than those with higher levels. Adherence to medications can be enhanced by 
education of patients and family members, improved dosing schedules, increased 
accessibility to healthcare, and improved provider-patient relationships (e.g. increased 
trust).[153] 
 
Improving medication adherence. 
Physicians should presume that patients have low adherence to their treatment and give 
clear and precise information about the expected benefits of treatment, the disease, and 
risks of progression.[154] 
 
Many techniques have been used by many health care providers to improve adherence to 
medication in their patients for many different diseases or health conditions. These may 
be general or aimed at specific target groups e.g. by age or level of education etc. One of 
these uses the AIDES acronym which is built on the principles of completing a 
comprehensive medication Assessment; partnering with patients to ensure 
Individualization of the regimen; choosing appropriate Documentation; providing 
accurate and on-going Education tailored to the age group and needs of the individual; 
and continuing Supervision after initiation.[155] Another system that has been used is 
the motivational interview method, which has been used in many health settings and has 
shown promise in psychiatry, HIV care and hypertension (see further discussion 
below).[156-159]  
 
 
Acceptance of glaucoma surgery 
Acceptance of glaucoma surgery is a problem in Africa for many reasons.  Most 
important is that the patients perceive no visual improvement after the surgery or are 
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afraid of the surgical procedure itself. There are very few studies about acceptance of 
treatment in Africa as most studies focus narrowly on the outcome of those who have 
undergone surgery.  In a study undertaken by the researcher in Northern Nigeria, 
acceptance of surgery was just 8% in patients in whom surgery was recommended as the 
treatment of choice.[160] Rumours may play an important role. In Kenya, those who 
accepted cataract surgery generally reported that people they knew had had a good 
outcome while those who refused surgery often knew someone whose vision worsened 
or even become blind after surgery. Many of these 'failed cases' were prominent figures 
in the local community. On being re-interviewed, several people admitted that they had 
actually never met someone who had undergone unsuccessful surgery but had only 
heard rumours.[161] 
 
A trial of health education in India of glaucoma patients offered early surgery or medical 
management, showed that acceptance of early surgery was higher amongst those 
receiving health education (65%) than those receiving usual care (35%). The study also 
showed that early surgery gave better IOP control than medical treatment.[162]  
Follow up 
Poor follow up is another very important problem that affects the management of 
glaucoma patients in Africa. In Ibadan, Nigeria 60.5% of glaucoma patients who were not 
blind failed to attend for follow up. The main reasons for defaulting were that they used 
the medicines and they felt all right, transport problems, fear of surgery, feeling better or 
no change with treatment. Patients who were more likely to dropout were younger, 
male, or they lived far away from the clinic. Patients with severe disease were more likely 
attend for follow up.[163] In Ghana, only 19% of patients attended follow up at 6 months 
and only 17% on topical medication had IOPs <22 mmHg.[164] In Nigeria, 60% of 
glaucoma patients failed to attend the hospital after one year, with young males being 
likely defaulters.[163] [163]Demographic factors also affect adherence to follow up.  In a 
study in a Glaucoma Clinic in San Francisco, being black was one of the factors 
independently associated with inconsistent follow-up (OR 7.16) as was lack of knowledge 
of the permanency of glaucoma blindness (OR 3.09) and not being counselled by 
glaucoma clinic staff (OR 3.6).[165] In India, independent predictors of poor follow-up 
included lack of formal education, poor adherence, and belief that follow- up is less 
important if one uses glaucoma medications and has no noticeable visual changes.[166] 
In another study in the US, black race, Latino ethnicity, unfamiliarity with the long-term 
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nature of treatment, lack of knowledge of the permanency of visual loss due to glaucoma 
and perception that it is not important to attend all follow-up visits were independently 
associated with inconsistent follow-up.[165] In a another study in African Americans in 
Connecticut, after screening for glaucoma, 69% complied with follow up, and 27% of 
these only came after being contacted once or more. In this prospective study, people 
who smoked, lived alone or had no car were less likely to comply with free follow up.  
Personal or family history of glaucoma had no significant impact on compliance.[167]  
 
Stage at presentation of glaucoma and acceptance of surgery in Nigeria 
 
Open angle glaucoma is painless and visual loss is gradual and insidious. In addition, in 
Nigeria there is a lack of primary eye care, which means that cases are not detected early, 
as occurs in high-income settings where adults often visit an optometrist. As a 
consequence people with glaucoma often present very late, frequently already blind in 
one eye with advanced disease in the other. This is reviewed in the paper titled:  
1. Primary open angle glaucoma in northern Nigeria: stage at presentation and 
acceptance of treatment. Abdull MM, Gilbert CC, Evans J. BMC Ophthalmol. 
2015;15(1):111. 
Data were collected from the hospital where the PhD study was undertaken. The study 
was carried out to assess the extent of late presentation and acceptance of surgery in the 
study area. 
 
 
 
 
 
 
 
 
 
 
 86 
Paper 4: Primary open angle glaucoma in northern Nigeria: 
stage at presentation and acceptance of treatment 
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Health education for glaucoma –rationale for using 
Motivational Interviewing 
Heath literacy - the degree to which individuals have the capacity to obtain, process, and 
understand basic health information and services needed to make appropriate health 
decisions, [168] has been associated with progression of visual field loss in glaucoma 
patients. For example, in a study in the UK, patients with poor health literacy had poorer 
compliance, worse understanding of glaucoma, and the condition was more likely to 
progress compared with those with adequate health literacy. This highlights the need to 
promote health literacy in patients with glaucoma.[169]  
 
A review of health promotion and the prevention of blindness in developing countries 
demonstrated three key components of effective health promotion:  health education 
should be directed at behaviour change to promote the adoption of healthy behaviour 
and to increase uptake of eye care services using an appropriate method of delivery such 
as mass media, face-to-face discussion or social marketing. This includes identification of 
barriers, a suitable setting and approaches that are acceptable and delivered by 
appropriately trained individuals. The second element is improvement in health services 
in terms of quantity and quality by addressing locally identified barriers, improving 
quality of information provided to patients to promote adherence to treatment and 
follow up. It is also important to improve other non-clinical aspects of care to make the 
services more accessible, affordable, effective and acceptable. The third component is 
advocacy to improve awareness of the importance of blindness prevention among policy 
makers and planners to increase resource allocation for eye care and influence 
implementation of these policies. The review also showed instances where health 
education had impact on blindness prevention efforts at various levels.[170]  
 
Research has demonstrated the benefit of health education in improving glaucoma 
awareness and uptake of services. For example, mass education in the United States 
reduced glaucoma blindness through influencing individuals at risk, such as people of 
African descent, to participate in regular ophthalmic care.[171] Similar findings were 
reported in a clinical trial in India of a counselling education package delivered by a 
paramedical worker. In this trial 65% of patients in the intervention arm accepted early 
compared with 35% in the usual care arm. The study also showed that early surgery 
offers better IOP control than medical treatment.[67]  
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An important aspect of health education is mode of delivery. In the United States, 
focused video instruction was an effective and efficient teaching intervention for 
disseminating health information in the waiting area of a clinic.[172] In the Netherlands, 
patients preferred the ophthalmologist, the nurse or a representative of the glaucoma 
patient society to provide health education.[173] In Shanghai, China, glaucoma clubs 
seemed to play a role in increasing patient’s awareness and knowledge about glaucoma, 
thus increasing compliance with medication.[174] In a specialist eye hospital in England 
patients benefitted from education programs on beliefs and compliance in glaucoma and 
ophthalmic nurses were effective teachers.[175] In Barbados, obtaining eye care from the 
single public ophthalmologic source was associated with an 80% reduction in the odds of 
poor awareness.[176]  
 
Knowledge of glaucoma in Nigeria is poor not just among patients, but also among 
health workers. [177] In a cross sectional survey of a population of 40 years or above in 
people attending ophthalmic outreach in Ethiopia, only 8/340 people (2.4%) were aware 
of glaucoma.[174, 178] In another study in India, only 8.7% had some knowledge of 
glaucoma.[179] Poor knowledge in a US study has also been linked to poor follow up 
among glaucoma patients.[180] 
 
Fear has been a recurring reason for not accepting surgery whether for cataract or for 
glaucoma. For example, in the Collaborative Initial Glaucoma Treatment younger age, 
being white, and having less education and a lower income were associated with greater 
fear of blindness.[181] Using fear as a counselling strategy could be a double edged sword, 
however: on one hand fear of blindness could be a source of motivation for improving 
adherence to medication[182] while on the other hand fear is known to be a disincentive 
to accepting surgery.[84]  
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Conceptual framework  
Efforts to improve health by increasing patient knowledge alone have rarely been 
successful. Two important models of patient education have been broadly described. 
These are the information dissemination model and the behaviour change 
model.[183]  
The information dissemination model involves information dissemination to patients 
using teaching, printed materials or multimedia such as videos and audio programs. This 
is the most commonly used system in patient education. Outcomes have been varied, 
successful in some instances, as outlined above, or failure as in a study of patients with 
hypertension where increase in knowledge did not affect adherence to medication or 
control of blood pressure over time.[184]  
The behaviour change model uses the behavioural diagnosis concept as the hallmark of 
patient education. This model identifies variables that positively or negatively influence 
the patient’s decision towards the desired behaviour. Behaviourally oriented programs, 
often with special attention to changing the environment in which patients care for 
themselves, have been consistently more successful at improving the clinical course of 
chronic disease.[185] Patient education should, therefore, ideally achieve a change in 
behaviour. A good example of behaviour change model in clinical use is the health belief 
model (HBM). The health belief model is one of the health promotion theories that are 
applied at the individual level. It can be used to illustrate the behaviour change that is 
needed to improve the clinical course of chronic diseases such as glaucoma or 
encouraging reluctant patients to accept care.[186] The model was developed initially in 
the USA to understand the widespread failure of people to accept interventions for 
disease prevention, such as screening tests for the early detection of asymptomatic 
disease.[187] Components of the HBM are perceived susceptibility, perceived seriousness, 
perceived benefits, perceived barriers and cues to action (Figure 2). These can all be 
applied to glaucoma.  
Perceived susceptibility: i.e., the individual’s perceived chance of getting the disease. 
This is likely to be very low in Africa 
Perceived seriousness: i.e., a self-judgment of the seriousness of glaucoma as a disease. 
This too will be low unless a family member or someone known to them has visual 
loss from glaucoma in which case the perceived seriousness is likely to be high. 
Perceived benefit: i.e., the person’s belief about the importance of presenting early for 
treatment or accepting surgery for glaucoma.   
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Perceived barriers: i.e., factors that militate against the pursuit of the required 
behaviour change outlined. This may be affected by many factors such as fear of the 
procedure or embarrassment of being thought blind.  
Cues to action: i.e., modifying factors that reinforce the threat level which lead to 
behaviour change.  
The perceived susceptibility and seriousness can increase the perception of the threat 
that glaucoma poses to the individual, which can, with cues to action, lead to the desired 
behaviour change.  
Modifying factors: In the HMB the modifying variables are demographic factors (age, 
sex, race and ethnicity), socio psychological factors (personality, social class, culture, 
education and peer group pressure) and structural variables (knowledge of or contact 
with the disease). These factors interact in a complex relationship to lead to 
likelihood of action to change or modify behaviour.  
Self-efficacy is the person’s belief in their ability to execute the behaviour change, in this 
case early presentation, acceptance of and adherence to treatment and follow up. This 
can also be affected by many of the modifying factors above. Barriers for control are the 
major challenges posed by glaucoma in Africa, which are: 1. disease factors such as early 
onset of glaucoma and [4] aggressive course,[102] higher prevalence,[24] surgical 
failure,[70] even with mitomycin C[69] and β radiation[71] and medical treatment 
failure[188]; 2. provider factors which include poor facilities and equipment,[189] lack of 
adequate skills[190] and limited treatment options; and 2; patient factors which include 
poor awareness,[191-193] fear and cost of treatment[84, 86, 154] and late 
presentation.[160] 
Despite there being little conceptual overlap between MI and the HBM, the HBM was 
used as a framework in order to integrate educational awareness raising elements (e.g. 
susceptibility and seriousness in HBM terms) with more motivational ones (benefits and 
barriers) which are potentially modifiable by MI.   
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Figure 3: Health Belief Model in relation to glaucoma and potential of 
motivational interviewing.1 
 
 
 
Challenges in health education  
 
In Nigeria there is no term for glaucoma, IOP or visual field defects in the local language, 
and a high proportion of the population in Northern Nigeria are not literate. In order to 
educate patients, a simple means of disseminating useful, easily understood information 
on glaucoma and its management had to be designed. 
 
In this study the important barriers for control, more specifically early presentation, 
acceptance of treatment, adherence to medication and follow up were identified. Armed 
with this knowledge an educational package was created and a suitable mode of 
presentation that is simple, easily taught and replicable was found. By consultation with 
experts in LSHTM, Motivational Interviewing was suggested as suitable delivery method 
that fits the criteria and has been tried in similar circumstances and been found to be 
effective.  
 
                                                            
1	Adapted and modified from: https://www.scienceandsensibility.org/blog/perception-is-
everything-understanding-the-health-belief-model		
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What patients know about glaucoma  
Glaucoma is a very difficult concept to explain to the ordinary patient attending our 
clinic and patients often have no understanding of what it means. Patients obtain 
different explanations about the disease from different sources. Most of the terms used 
are descriptive of the pattern of visual loss or the symptoms that the patients experience. 
In order to create an easily understandable counselling guide for glaucoma, it was 
necessary to understand what the patients think about the disease. To do this a series of 
focus group discussions and in-depth interviews were carried out with new patients, old 
patients, carers of such patients, patients who were blind from the disease, patients who 
had undergone surgical treatment, and those who refused surgical treatment. As many 
patients consult traditional healers before coming to the hospital, it was also necessary 
to discuss with the traditional healers to find out what they know about glaucoma, what 
treatment they offer and what they say to patients. Information obtained from these 
sources was used to phrase the counselling intervention to fit patients’ current 
understanding of the disease. 
 
 
The following paper describes what patients know about glaucoma and their general 
attitude in the management of the disease. 
1. Glaucoma, “the silent thief of sight”: patients’ perspectives and health seeking 
behaviour in Bauchi, northern Nigeria. Abdull MM, Chandler C, Gilbert C.. BMC 
Ophthalmology. 2016;16(1):1-9. 
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Paper 5. Glaucoma, “the silent thief of sight”: patients’ 
perspectives and health seeking behaviour in Bauchi, northern 
Nigeria  
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Figure 4: The silent thief, printed leaflet given to every new patient attending the 
glaucoma clinic 
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Chapter 3: Motivational interviewing (MI) – theoretical: 
use in other conditions 
Motivational interviewing (MI) was developed by Miller, W. R. and S. Rollnick in 1983, 
has a connection with the trans-theoretical model (TTM) of health behaviour change. 
This model describes six stages patients go through: pre-contemplation, contemplation, 
preparation, action, maintenance, and termination.[194] The TTM is intended to provide 
a comprehensive conceptual model of how and why changes occur, whereas MI is a 
specific clinical method to enhance personal motivation for change.[195] The most 
obvious connection between motivational interviewing and the stages of change is that 
motivational interviewing is an excellent counselling style to use with clients who are in 
the early stages. Pre-contemplators do not want to be lectured to or given “action” 
techniques when they are not ready to change. Likewise, contemplators, who are 
considering the possibility of making a change but are not quite ready to make a 
commitment, are resistant to more traditional approaches that encourage (or try to 
force) them to make changes for which they are not yet ready. [196] A technical 
therapeutic definition of MI is:  “Motivational interviewing is a collaborative, goal-
oriented style of communication with particular attention to the language of change. It is 
designed to strengthen personal motivation for and commitment to a specific goal by 
eliciting and exploring the person’s own reasons for change within an atmosphere of 
acceptance and compassion”. 2  It is a client-centred counselling style for eliciting 
behaviour change by helping clients to explore and resolve ambivalence.[197] 
Motivational interviewing is built on four fundamental processes. These are Engaging, 
which is the relational foundation, Focusing the strategic focus, Evoking the transition to 
MI, and Planning, which is the bridge to change. The underlying spirit of MI is that of 
Acceptance, Compassion, Evocation and Collaboration. Critical in MI is the expression of 
empathy, that is seeing the world through the client’s eyes, thinking about things as the 
client thinks about them, feeling things as the client feels them, sharing in the client's 
experiences. The guiding principles of MI are:[198] 
a. Resistance of the righting reflex,  
b. Understanding the patient’s motivation,  
c. Listening to the patient and  
                                                            
2 William R. Miller, Ph.D, Stephen Rollnick, Ph.D: Lecture: Motivational Interviewing, What It Is, 
How It Works, How To Learn It, Motivational Interviewing Workshop, Cardiff, Wales, UK. 10-12 
June 2012. 
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d. Empowering them.  
 
In practice MI uses the three core skills of asking, listening and then informing.[198] The 
listening is usually reflective. Listening for “change talk” is divided into preparatory 
change talk (DARN below) and mobilising change talk-resolving ambivalence (CATs) 
below. 
i. Desire to change- e.g. wish 
ii. Ability to change- e.g. could  
iii. Reasons to change- e.g. if 
iv. Need to change- e.g. I ought to 
v. Commitment- e.g. I am going to,  
vi. Activation (willing, ready, preparing) 
vii. Taking steps-statements about action taken. 
 
This change talk is usually responded to by: (EARS)* 
i. Elaborating: Asking for elaboration, more detail, in what ways, example, etc. 
ii. Affirming – commenting positively on the person’s statement 
iii. Reflecting, continuing the paragraph, etc. 
iv. Summarizing – collecting bouquets of change talk 
 
There is a specific way of giving information and advice in MI* 
i. Get permission 
ii. Qualify, honouring autonomy 
iii. Ask – Provide – Ask 
iv. For suggestions, offer several, not one 
 
The important components of MI include building rapport, avoiding resistance, selecting 
an agenda, assessing readiness to change, addressing ambivalence, determining the level 
of importance of the issue and evaluating the level of the patient's confidence in his or 
her ability to change.[159]  
 
Motivational interviewing has shown promise in adherence to treatment in outpatients 
in psychiatry. For example, in a trial of treatment adherence among psychiatric and 
dually diagnosed patients, the proportion of patients who attended their first outpatient 
appointment was significantly higher in the MI group compared with control group.[158] 
In substance abuse, a Cochrane review concluded that MI could reduce the extent of 
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substance abuse compared to no intervention.[199] In a randomised trial in HIV patients 
failing or initiating ART care, 29% of the treatment group achieved >95% adherence to 
antiretroviral therapy (ART) compared with only 17% in the control group. After 
controlling for ethnicity, the intervention group had 2.75 times higher odds of achieving 
more than 95% adherence than controls.[157] Trials of MI for smoking cessation among 
adolescents and adults showed that there was a higher odds of cessation in the MI group 
(OR 1.45; 95% CI 1.14-1.83).[200] However, many of the reviews comment on the variation 
in quality of study designs, and the role of publication bias. 
 
Fidelity of Motivational interviewing  
Fidelity is the extent to which delivery of an intervention adheres to the protocol.[201] In 
MI many measures of fidelity have been used but the most popular is the Motivational 
Interview Treatment Integrity scale (MITI). This is a brief scale designed to evaluate the 
integrity of the use of MI. It is a cost-effective and focused tool for evaluating 
competence in the use of MI. It can be used for self-evaluations, assessment of the 
effectiveness of teaching strategies, and individualized feedback to improve MI 
competence for clinicians in training.[202] The MITI assesses six criteria: empathy, MI 
spirit (autonomy, evocation and collaboration), MI adherence (asking permission, 
affirmation, emphasis of control and support), MI non-adherence (advise, confront and 
direct), the types of questions (open or closed) and the number of reflections. It is an 
invaluable tool in research for measuring fidelity of MI.  
 
Training implications  
Training in MI has been done in several ways with workshops being the traditional 
method comprising two to four days of lectures, role-play or simulated patients. 
Teleconferencing [203] and web-based training have also been used. A two-day training 
workshop showed an increase in skills in staff of probation service but this was not 
maintained at three months. [203] In a study with medical students trained in MI for 
smoking cessation, there was no difference in training through role-play or using student 
colleagues when teaching basic MI skills for smoking cessation.[204] Motivational 
interviewing is a skill that can be taught at most levels. A study showed that peer 
outreach workers (paraprofessionals in HIV care) can be trained in MI with good 
fidelity.[205] 
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Learning motivational interview; our experience 
 
The purpose of the next paper is to document our experience learning and practicing MI. 
As a first step it was necessary for the principal researcher and the interviewers to be 
proficient in the delivery of MI. The literature has shown that MI can be easily taught to 
people with a wide variety of skill levels. The principal researcher attended a series of 
training sessions about MI, and in turn used what he learnt to train three interviewers. 
Together they trained and practised to reach a level of proficiency that was sufficient to 
adapt the counselling technique and used it with good fidelity in the study.  
The following paper, which has been submitted, documents our experience learning and 
using motivational interviewing.  
1. Learning Motivational interviewing, our experience. M M Abdull, F 
Muazu, Joy Rengwen, A Ahmad Submitted to Motivational 
interviewing training research implementation practice (MITRIP) 
journal.  
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Paper 6: Learning motivational interview; our experience. 
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Glaucoma is a chronic blinding eye disease.  It is the second commonest cause of 
blindness worldwide [5] and in Nigeria. [7] Glaucoma is of particular concern to 
Africans because of the unique challenges they face.[206] Black populations have a 
higher prevalence of glaucoma in all age groups [22, 207] and patients in Africa often 
present very late to the hospital with advanced disease.  [51, 208, 209] Blacks are also 
less responsive to both medical and surgical treatment for glaucoma.[58, 94] They also 
have reduced (limited) access to treatment and are less aware of the risks of having 
glaucoma.[58, 192]  Accepting surgery is a particular problem because of fear of 
blindness resulting directly from the eye surgery, or just plain fear of any type of 
surgery[210] but also because it is not associated with improvement in vision as in 
cataract. 
 
Motivational interviewer 1 
 
As a clinician dealing with patients, I always gave instructions to patients about how to 
use medication, how to look after them after surgery, and how to come to hospital for 
follow up.  I have never had any formal training in counselling or how to talk to patients 
apart from what I learnt in Medical School and in specialty training.  The training most 
doctors have is to give directives or information to patients, not really knowing whether 
the patients grasp what we were communicating or not.  When patients do not return for 
follow up, or fail to use their medication as prescribed, we tend to show concern for their 
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health or even get angry with them for not abiding by our instructions.  We get surprised 
when despite the severity of the patent’s problems they fail to adhere to medication or 
instructions.  We talked to patients, gave them materials to read but all to no avail. 
 
I first heard about motivational interviewing (MI) from a meeting with one of my review 
panel members.  I did some research about MI and from what I gathered in the literature 
review, there was no doubt that MI has worked well.[211]  It was quite fascinating for me 
to learn that a counselling technique that can be conducted in an hour or less and with 
one or few sessions can help people addicted to drugs [199, 212].  So if MI can get people 
to stop drugs, imagine what it will do to patients just to continue using their eye drops 
without fail?  At that time I did not even know that it had been used in other medical 
fields such as diabetes, hypertension, [156] diet control or just plain drug adherence in 
many diseases.  My major concerns are for my glaucoma patients to come to hospital 
early, accept surgery or laser treatment if indicated, adhere to their medication regime 
and to continue their follow up schedule for monitoring intraocular pressure and general 
progress of their vision.  I searched the literature to see if anyone had used this to get 
glaucoma patients to adhere to or accept treatment for blindness prevention.  My search 
came up with an instance where MI has been tested for feasibility in glaucoma 
management and was found to have potential for improving adherence.[213] 
 
Soon after I was introduced to Jim McCambridge.  We had a discussion and he gave me a 
book titled Motivational Interviewing in Health Care.  [214]  It was most interesting to 
read the book.  As I read further, it all began to make sense.  Within a short time I 
finished the book and started over again.  This time I started practicing what I had learnt 
on my friends.  I found among other things that I became a good listener, and was able to 
understand people more.  I had a lot of practice, asking open-ended questions and 
responding with two or more reflections per question.   
 
On coming back to my clinic I shared my book with my assistant.  Together we met every 
evening to practice what we had learnt from the book.  After some time, we started 
interviewing each other as simulated patients using role play which has been found to be 
effective as a learning tool.[215] We did that a lot before starting to practice with real 
patients.  We recorded every interview and later sat down and played it back to critique 
ourselves.  We sought to find out how many times we used closed questions as opposed 
to open-ended questions, the number of reflections we gave for each question, and also 
affirmations and summaries.  It was quite surprising for me to find out much later that 
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something similar to that called MITI (Motivational Interviewing Treatment Integrity 
Scale) is actually being used for fidelity testing in MI, and there are people who do just 
that.[216]  
 
At that time we had the tendency to give too much and often unnecessary information to 
patients.  We were working on ask, listen and tell.  We fed patients with too much 
information about glaucoma even when they did not ask for it. 
 
I heard about the introductory course to MI in Cardiff, South Wales, so I registered and 
attended.  Prior to this time, I had not had any training on MI.  The course was very 
important to me.  It exposed me to what MI really is from W. Miller and S. Rollnick.  
There was an opportunity to discuss and practice with people who had been involved in 
counselling and MI for some time.  It was a novelty for me to meet and even have 
discussions with W. Miller and S. Rollnick, who were quite pleased with my interest in 
MI.  As the only ophthalmologist there - probably the only person from sub-Saharan 
Africa - and the only person not working either as a counsellor or in the addiction field, I 
was a curiosity for many participants, and they wanted to hear more about what I was 
doing and how I thought MI will help my patients.  I had the opportunity to trade stories 
with many interesting people and share ideas with them and also learned a lot from 
them. 
 
Furthermore I attended a workshop and conference on MI in Venice, Italy, and I had 
another opportunity to meet with many people who were experts in or working with MI.  
I had the opportunity to discuss with such big names in MI as T. Moyers from the US. 
 
Ever since attending the two workshops and conference, I feel I understand MI much 
better than I did before.  I have been sharing all that I have learnt about MI with my three 
assistants who have never had any training in counselling before.  They are graduates 
who majored in physiology, microbiology, and English respectively.  We spent more than 
a month reviewing the MI book, publications about MI and practicing with each other 
and with patients.  As before, we recorded our interviews and reviewed them, giving 
scores for open ended questions, reflections, affirmations and good summaries.  With 
further training I realized that we would often finish a 45-minute interview without 
giving the patient any specific information about glaucoma, but still getting them to 
commit to have surgery by the end of the interview.  
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It was especially interesting for me to find out that even middle cadre staff or workers can 
be trained to deliver MI.[217] Thinking about this, it means that if effective, we could 
easily train existing staff instead of having to employ specialist trained counsellors who 
are scarce and their employment will cost us more.  Since my contact with MI I have 
shared what I know with four ladies who will eventually work in the clinical trial.  MI was 
originally designed for western audiences, but over time, people have tried it in other 
ethnicities and in many countries even in sub-Saharan Africa.  Studies have been done 
and it has been found to have good outcome in people of different ethnicities.  [157] This 
is also one of my motivating factors that perhaps it will also work in the ethnic 
population I want to apply it to.  
 
Of course, as people learning MI, we had a lot of challenges, some to do with our patients 
others with us.  One of the bigger challenges is doing the interview in a language other 
than English.  With English, there were simple and familiar sentences and phrases that 
we could use.  Sometimes it was difficult framing a question in the local language, Hausa, 
or a response that translates to or portrays the appropriate meaning intended.  But 
gradually we developed a series of ways to ask particular questions in the language so 
that the patients can understand.  A particular difficulty is affirmations in that language, 
which sometimes in the middle of an interview seemed patronizing to patients.  We had 
to find ways around that.  When practicing DARN-CAT, we collected phrases especially 
in commitment and activation language and translated them into Hausa with the help of 
lay people and patients.  We came up with simple, easily understandable phrases, 
sentences, and responses that fit the local colloquy. 
 
It is not enough for us to adopt and adapt MI and just start using it without evidence that 
it will have any impact on the management of our patients.  That is why we started our 
planned randomized clinical trial to assess the impact of adapted MI on acceptance of 
surgery, adherence to treatment, coming for follow up and ultimately control of 
intraocular pressure in our glaucoma patients.  When the trial is over, depending on the 
outcome, we can then use the evidence we have to plan training of counsellors to 
routinely interact with outpatients.  
 
We have now been interviewing patients for about 12 months.  Over this period, we have 
learnt a lot about MI as well as about our patients.  There are some unique challenges 
that we face in this place that may not be the same in other places.  Some of these 
challenges are discussed below. 
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Some participants have this blind faith in God that makes them not respond well to 
questions or prompts on what they will do or intend to do.  They always say things like 
“only God knows” or “God will do it” or “It is in God’s hands” or “That is the way God 
wants to see them”.  For instance, you ask someone what strategy will he use to remind 
him to use his medication on time?  The answer will be “God will do it” or something 
similar.  I usually go ahead to suggest examples like how about asking his wife or anyone 
at home to remind him of the time for medication?  It becomes difficult to get such 
people to commit or take action as they expect God to do that for them. 
 
Many of our participants are used to being directed to do things, so they find it strange 
that we should ask their view on something or what they intend to do.  In many there are 
clear signs of discomfort, as they think they are being assessed.  One patient actually 
asked if marks would be awarded to him, as if it was an examination.  Their expectation is 
to be told what to do by us not the other way round.  An elderly woman in the clinic once 
said “Please doctor, stop asking me what I would do.  Just tell me what I should do”. 
 
Participants tended to open up more to talk about the eye problem, how it started or 
presented, what they did etc., but not what they would do to help themselves.  Some just 
don’t want to disappoint the MI interviewer so they say what they think we want to hear 
and it becomes a task to get them to tell the reality.  I found that they were more open 
with my assistants than with me.  They think as their doctor, I will not be happy if they 
told the truth that they have not been regular on their medication, this is due sometimes 
to “white coat fear”.  It is partly for this reason that the interviews are not done by 
doctors in the trial. 
 
Some have too much dependence on family members, guardians, or husbands that they 
cannot even show intent to commit to anything on their own.  There are instances where 
patients would be hesitant to respond to prompts, until they go back home to consult.  
They actually even want the questions we asked to be directed to the husband/son etc. to 
answer for them.  This has to do with local customs where parents speak for their 
children or husbands for their wives.  They are not used to having their opinions heard or 
being involved in making decisions even about their health or welfare.  
 
Some participants needed very long and detailed explanations about confidentiality 
before they could relax and have a proper discussion with the interviewer.  Some are 
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afraid that if they told the truth the information will get back to their employers or 
sponsors with adverse effect.  In these cases engagement took more than half the 
interview.  
 
The usual presentation of our patients is with blindness in one eye and advanced disease 
in the other.  One role MI can play here is to get the interviewed patients to refer their 
first-degree relatives for screening so that the disease can be diagnosed early before major 
damage to vision ensues.  Being a first degree relative is one of the important risk factors 
for glaucoma,[218] the prevalence of the disease being higher in them[219] therefore it 
gives us an opportunity to target those who are at risk. Motivational interviewing is an 
exciting thing for us here.  We are yet to know the impact it is making on our patients 
until we conclude the randomized clinical trial.  We are not going to pre-empt the trial 
but we are still hoping it will be a key that will help us to reduce the alarming rate of 
blindness from glaucoma in this locale.  
 
 
Motivational interviewer 2 
 
My journey with MI started about two years ago, when I was just starting to get the hang 
of my job.  It began when our ophthalmologist came back from a trip to London.  I felt 
that there was a slight, subtle, almost imperceptible change in his attitude in general 
towards both patients and the people he worked with.  I never really gave it a second 
thought until he told me about MI.  It was the tool he was proposing to be the 
intervention in his impending research project. 
  
At first I was curious about this form of counselling, but as l read about it, I was intrigued 
and surprised.  I realize it could just be the tool for boosting self-confidence, self-
liberation, and self-realization of boundaries. 
 
Motivational interviewing is a form of counselling that encourages the counselled party 
without pressure.  It is focused on guiding rather than directing and support is given by 
exploring a string of possibilities for a particular situation, sort of like a multi-
dimensional way of analysing a situation.  Unfortunately, people here are more 
comfortable at getting directives from personnel.  Many a times participants feel they do 
not have what it takes to make simple decisions, such as agreeing to an MI session, or 
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even coming to the hospital for treatment.  They tend to lean on either the interviewer or 
seek permission from influential family members.  
 
There’s also evoking involved in MI, which gives room to explore one’s inner self, thus 
establishing trust.  Once this is accomplished, more issues may surface in the discussion 
and with open ended style of questioning, focusing on important issues, setting priorities 
and setting agendas, change talk may be achieved which leads to planning practical 
positive change. 
 
My training in this fascinating tool involved role-playing and lots of practice.  I had 
plenty of opportunity to do that and because I developed a deep interest in it, I 
inculcated it in my daily interaction with people, be it at home with my family or at my 
working place.  My job entailed obtaining consent from patients willing to participate in 
our research project activities such as focus group discussions, one on one interviews, 
interviews with traditional medicine people, even ordinary conversations with patients 
and their escorts on compliance issues. 
  
Of course there were challenges that I had to find a way of overcoming.  I got some 
suggestions on how to address some from my MI mentor and some I had to figure out 
myself.  For example, in spite of assurance of confidentiality, some patients still harbour 
trust issues.  There was an instance where a female patient was scared of having an MI 
and hurriedly left under a false pretext and never returned.  Some patients do not want to 
discuss any topic no matter how far fetched or trivial the issue is from the focus of 
discussion.  The culture of our society is one that looks upon counselling as intrusive.  
This raises suspicion and most people react in various ways in defence to barricade any 
form of discussion with them, thus comes the importance of sincerity and empathy on 
the part of the interviewer.  This I think is the basis for building trust, without which 
there won’t be a holistic MI interview. 
 
There was the challenge of relating meanings from the English language to Hausa, which 
is the local language most of our patients understand.  We also encountered many clients 
in denial.  Most of our clients are end stage glaucoma patients.  They tend to be very 
conscious of their non-sightedness thus retreat into their shells or attack in defence.  This 
is mostly as a result of societal taboo or from oppression right from their homes.  
Uneducated patients, especially women, prefer to have MI sessions with a relative present 
with an inclination to redirect questions meant for them to the relative. 
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Motivational Interviewing is flexible enough to be used by moms with children’s 
tantrums, doctors with their undecided patients, teachers and their students, police 
interrogation, even in prisons such as those under Parole and one’s self for dealing with 
ambivalence, the list is almost limitless.  Any change or decision made as a result of a 
well conducted MI is mostly done with conviction and no matter the outcome, the client 
always feels responsible with no ill intent or blame because the decision was self-made 
without goading, rather it is just another lesson learnt and will mostly be viewed as part 
of experience, which is the best teacher.  
 
In general, MI promotes the feeling of “you have what you need’’.  It is a continuous 
journey filled with lots of experience; it is a door way to a whole new world of possibilities 
waiting to be explored.  I have come a long way with it, learnt a lot from it, benefited 
from it.  I think I am a better listener and it makes one to look at problems from different 
perspectives, giving a deep insight to situations.  I am looking forward to learning more 
of it. 
 
Motivational interviewer 3 
  
The training started with four of us present; that is three interviewers, and our doctor 
who is the resource person.  The training lasted for a week initially, and then 
subsequently we started practicing with ourselves and with some clinic staff. 
 
On the first day of the training, Dr Abdull briefed us on the general overview of the 
disease (glaucoma) beginning with the structure of the eye, then the disease itself.  It was 
interesting to know about glaucoma as an eye disease, it’s effects, it’s treatment, and it’s 
prevalence around the world.  Dr Abdull took his time to elaborate on each topic so as to 
help us get acquainted with the disease, which will help us in the course of the research. 
 
Motivational Interviewing was introduced, the history of MI, how it works and how to 
learn it.  Before then we were given some material on MI to read and get acquainted with, 
including the book by Rollnick, Miller, and Butler (Motivational Interviewing in Health 
Care).  It was a little boring at first before the introductory section but as we started the 
training it all began to make sense and became more interesting for me.  The first for me 
was having the knowledge that MI is a client’s self-motivation interview unlike other 
counselling styles.  Motivational interviewing has to do with asking open ended 
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questions, affirming, reflection and summary (OARS) which during the course of our 
training we learnt to be the basic skills of MI, used to motivate a client towards change 
and to avoid the righting reflex. 
 
During the training we learnt the fundamental processes in MI, which are engaging, 
focusing, evoking and planning.  We were also lectured on how to use importance scale 
ruler in setting priorities, agenda setting, recognizing change talk (DARN-Desire, Ability, 
Reason, Need) mobilizing change talk (CAT-Commitment, Activation, Taking steps) 
responding to change talk (EARS- Elaborating, Affirmation, Reflection and Summary) 
and avoiding discord and sustain talk.  In the course of the training we practiced each 
topic we were taught.  We had difficulties during practice and were tense, especially if Dr 
Abdull was present, having the fear we won’t do the right thing.  Sometimes we were 
assigned roles to play, one being the client another the interviewer and the other as the 
observer, after which we switched roles.  Sometimes we brought in a patient and one 
person interviewed while others listened, after which we all analysed and critiqued the 
session.  We had take-home assignments for each day, such as to translate some English 
words and phrases into Hausa since it is the commonest language used among our 
people.  There were days when we watched videos from YouTube, which helps us see 
interviews done by professionals.  The training periods were so serious that we had to 
come to the hospital during weekends.  
 
The most interesting part of the training was how we practiced and dramatized each 
topic, and the most challenging part was the translation of what we learn in English into 
Hausa.  Other challenges we experienced were listening actively during an interview 
session while being conscious of reflecting and at the same time asking open-ended 
questions, also knowing the fact that one is being recorded to be assessed.  At times I go 
back home discouraged, especially if I did not perform well in the training class.  I had 
serious problems using Hausa during translation and interview sections, and I remember 
Dr Abdull telling me the other interviewer was better than me, which made me pick up 
the challenge to do better.  I had to practice at home with my family members using 
Hausa as much as possible.  At the end he was very pleased with my progress, which 
made me happy.  One other problem I encountered was how to re-direct a client who is 
going out of the context during an interview without them feeling interrupted, most 
times I allow them go out for a long time.  After listening to one of my interviews, Dr 
Abdull made me realize my mistake, so I was able to effect the corrections he made in my 
subsequent interviews. 
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My first interview with a client was not too good, because I was conscious of my 
questions, reflections, and summaries.  Most times I summarized instead of reflecting, 
and asked closed questions.  Fortunately for me, I had an easy flowing patient, and I 
could have explored more if I had asked good open-ended question.  Subsequently I 
became less conscious and I applied my skills at ease, though still improving by 
practicing and learning from Dr Abdull and my colleagues.  At the beginning of the pilot 
study, most interviews lasted for 15-25 minutes but Dr Abdull insisted that a good MI 
should last for at least 30-60 minutes.  As time went on, there was an increase in the 
length of time in my interviews (25-45 minutes).  All interviews were recorded and some 
were listened to, and analysed by Dr Abdull.  Most interviews were carried out in Hausa, 
except for a few that used both Hausa and English at the same time.  Discussions in 
interview sessions were centred on acceptance of surgery, medication, follow up and 
knowledge about the disease glaucoma.  After each interview a form is filled in with their 
study number, duration of interview, their comments, and the interviewer’s comments. 
 
However, most of the challenges we had during interview sessions were with patients 
that have some education, who always feel they know it all.  Some believe they are doing 
us a favour by participating in the study.  Recently a man was asked to cooperate during a 
session and his response was “Do it anyhow, after all it is for your own good, I am only 
helping you do your job”  
 
Those that are well educated and those that are not educated completely tend to see the 
need to talk things out.  I also had a problem with non-literate housewives who are 
completely dependent on their husbands.  Some women, whether literate or not, depend 
on their husbands for decisions.  A woman once said whatsoever her husband orders her 
to do is final.  In the course of the pilot study I was privileged to interview about twenty 
patients, mostly male.  Most of the female patients preferred sessions with a relative or 
her household head present.  Most patients feel reluctant to talk at the beginning of the 
interviews, but in the middle of the session they open up into discussion.  
 
Professor Clare Gilbert visited us towards the end of the pilot study and went through the 
MIG (Motivational Interviewing for Glaucoma) interview forms and commented on 
them.  Though I was tense during her visit I later became more encouraged and confident 
after her affirmation.  We had a challenge during her visit with a patient who was willing 
to have MI but her husband refused.  We had to revise the MIG form, giving a column for 
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reasons why an interview did not take place.  In the course of the research, I had different 
experiences.  I had interview sessions with patients who will not want to talk no matter 
how you try to evoke.  Some might be due to fear and lack of exposure (especially 
women), and will not want to come back for another session if they are asked to come 
back.   
 
After the pilot study, I had the privilege of undergoing another training on MI.  During 
the training we had a new staff member.  Dr Abdull repeated everything we did in the 
first training; we were assigned roles to play, watched YouTube, and also tried to create 
possible open-ended questions that we might like to ask.  That also helped me to improve 
my skills on MI.  All through the study to date I’ve had the privilege to counsel many 
patients along with their relatives in over eighteen sessions. 
 
Learning and practicing MI was not an easy task.  It’s one of the greatest challenges I had 
in my lifetime.  However, it has given me a new way of interacting with people and 
getting people to do what they are supposed to do without stress.   
 
I as a whole have helped patients in the clinic feel cared for and being attended to, it 
gives them the confidence to approach their problems and want to come back again for 
hospital care.  As an individual, learning MI has been a great challenge, getting perfect at 
it is another process, which one has to learn to listen and attend to patients, and let your 
patient become your teacher.  MI has helped one to interact with people and help them 
motivate themselves. 
 
Motivational interviewer 4 
 
A Tuesday was the day my Team leader began training me as a motivational interviewer.  
It was also the very first day I heard about MI.  The session commenced in the afternoon 
with two of those already trained in MI in attendance. 
 
On the first day of the training, I was briefed on the historical background of MI and how 
it is being used in health care.  Initially, when I heard the term ‘motivational 
interviewing’ the first thing that came to my mind was questioning.  I thought it was just 
like the ordinary interview done by journalist but with a slight difference, and since it is a 
motivational interview all the interviewer has to do is question the patient/client, after 
which the interviewer counsels, advices, and convinces patients/client on what the 
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interviewer thinks is best and right for patient/client.  After the briefing my perception 
changed and I thought for a while, this is going to be a great challenge.  Though I was 
ready to face the challenge, at the same time I had fear of not doing the right thing or 
disappointing my employer. 
 
The first lecture was about the basic skills used in MI, which are open questions, 
affirmations, reflections, and summaries (OARS).  It was really interesting learning these 
skills for the first time.  After the lecture, we all practiced the skills together.  I was given 
the book on Motivational Interviewing in Health Care to read in order to have more 
insight on what I was being trained in.  As the training continued, I learnt a lot about MI, 
some of which included the communication styles in MI (i.e. directing, guiding, and 
following), and the fundamental processes, which are engaging, focusing, evoking, and 
planning.  We practiced every topic after the training.  This phase of the training lasted 
for two weeks.  I was given articles to read and also referred to YouTube to watch MI 
videos done by professionals. 
 
The second phase of the training was on glaucoma eye disease.  It was not my first time of 
hearing about the disease, so it did not sound new to me, but all I knew was that it was 
an eye disease and that’s all I could say about glaucoma.  The training started with a 
lecture on the eye itself.  A labelled diagram of an eye was used in the lecture.  I learnt 
about parts of the eye and their functions.  Initially, I thought blindness caused by 
glaucoma could be reversed just like in the case of cataract.  In the course of my training, 
I was able to know the difference between the two eye diseases (glaucoma and cataract). 
 
The whole training lasted for a month and within that period I became familiar with the 
skills, styles and fundamental processes of MI.  Since then patients have been assigned 
for me to interview.  My first interview was nothing to write home about.  I was really 
tense before and after the interview.  After every interview, we all sat and listened to the 
interview, and then our trainer analysed and critiqued it.  He said the essence of 
analysing and critiquing is not to make me feel bad but so I can realize my mistakes and 
help in improving my skills.  The first problem I encountered was how to ask open 
questions - I had asked two open and closed questions in a row instead.  Summarizing 
was also a problem as I summarize unnecessarily.  Affirmation and reflection were a lot 
easier to learn.  Another major problem was having short interviews.  A good interview is 
supposed to last for thirty minutes or more.  I had a problem meeting the appropriate 
time frame given for an interview.  So, with the help of the analysis and critique, I was 
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able to realize my shortcomings.  I sometimes experience nervousness before and after 
interview.  I hope to overcome that soon. 
 
I had interviews with patients with different personalities, some co-operative and some 
not co-operative.  I could remember one fateful day (though I can’t remember the precise 
day) I had an interview with a very co-operative patient, so when the interview was 
listened to, our trainer said it was a good interview because I was able to overcome most 
of my shortcomings in the previous interview and so he affirmed me.  That day I went 
home happy, I couldn’t help but to pick my phone and I call my sisters and told them 
that ‘’I have made progress in my place of work today’’.   
 
Some of the problems I had in the course of my training were interviewing old people.  I 
could remember interviewing an old lady who got scared when I told her that we are 
going to have a discussion with her concerning her eye health.  Her facial expression 
changed immediately and asked ‘‘has some terrible thing happened to my eye?’’  So I 
tried calming her down though she agreed to do the session but one could see it all over 
her that she was not very comfortable and refused the refreshment I offered her.  Another 
encounter was with an old man whose interview began smoothly but along the way he 
felt the absurdity of the interview since he is not sure if his medical bills will be taken 
care of, saying “Are you people going to be responsible for my medical bills with all this 
questioning?’’  Most people feel the importance of being part of this research and their 
response is in most cases “I am here to be treated, so just do what you think is right’’.     
 
The languages we use for MI here with our patients are English and Hausa depending on 
their choice.  Learning MI was really a great challenge to me because, as an interviewer, 
you have to be conversant with the two languages.  Most of the clients here are Hausa 
speakers though we do get English speakers too, but on rare occasions.  One of my 
challenges was translating English into Hausa.  
 
With reference from the Motivational Interviewing in Health Care book I read, MI helps 
in building up people’s confidence.  It also communicates, “You have what you need’’ 
instead of ‘’I have what you need’’.  Motivational interviewing is a method for helping 
people explore their own motivations. 
 
Motivational interviewer 1 
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Knowing our limitations with MI, such as our level of training, the language, different 
culture, different conditions and disease, we hold no illusions that we were doing “by the 
book MI”, therefore we have termed it adapted MI.  We are applying the core principles 
of MI under different circumstances aiming to get that change talk or commitment for 
change. 
 
It is now more than two year since my first contact with MI.  We have carried out a pilot 
study of adapted MI in improving uptake of glaucoma surgery or laser.  The unpublished 
results of a pilot study have shown some increase in acceptance of surgery or laser with 
MI.  To ensure that we were doing the right thing considering all the limitations we have 
about MI in a different set up, we intend to send some scripts for some form of MITI 
coding.  Some preliminary assessment of some of our interviews by experts has shown 
them to be okay considering all the limitations above. 
 
The main trial of adapted MI on acceptance of surgery or laser has just started here in 
Bauchi.  Eligible patients are those diagnosed in the clinic with glaucoma that have been 
recommended surgery or laser treatment.  These patients are randomized to either have 
usual explanation from a doctor plus an adapted MI session with an interviewer, or just 
the usual explanation by the doctor.  Those randomized to MI are further assigned at 
random to one of two interviewers.  The expected major outcome is having surgery 
within a specified period of the given surgery appointment date for the patient.  
 
Learning MI has been a novel, exciting and enriching experience for me.  It has been a 
journey of discovery for the impact it has made not just on my professional working life 
but on my personal life and relationships as well.  I am a better listener since I was 
introduced to it.  I am more emphatic when dealing with my patients and other people.  I 
now try to understand things from their own perspective.  I no longer confront my 
patients or indeed other people with the righting reflex telling them what to do.  I guide 
them on this journey of self-motivation till they express their opinion on the why, when 
and how they plan to achieve the change for the erstwhile elusive goal we seek.  
 
Motivational interviewing has shown some promise in the pilot study that we did.  If the 
trial shows that MI certainly works, I think we can count that as an innovation that can 
be easily replicated and scaled up to help not only glaucoma patients but patients with 
other chronic diseases where poor acceptance and adherence to treatment are a 
challenge. 
 131 
 
ACKNOWLEDGEMENTS 
1. British Council for Prevention of Blindness for funding the study 
2. Professor Clare Gilbert my supervisor 
3. Dr Jim McCambridge my MI adviser and teacher 
4. Staff of Eye Clinic ATBUTH for their cooperation and support 
5. Students and staff of ICEH/LSHTM London 
6. Management of ATBUTH 
7. Seeing is Believing and Standard Chartered Bank for financial support 
8. LSHTM 
 
REFERENCES 
 
Abdull, M. M., Sivasubramaniam, S., Murthy, G. V., Gilbert, C., Abubakar, T., Ezelum, C., 
& Rabiu, M. M. (2009). Causes of blindness and visual impairment in Nigeria: the Nigeria 
national blindness and visual impairment survey. Invest Ophthalmol Vis Sci, 50(9), 4114-
4120. doi: iovs.09-3507 [pii] 
 
Adekoya, B. J., Akinsola, F. B., Balogun, B. G., Balogun, M. M., & Ibidapo, O. O. (2013). 
Patient refusal of glaucoma surgery and associated factors in Lagos, Nigeria. Middle East 
Afr J Ophthalmol, 20(2), 168-173.  
 
Balo, P. K., Serouis, G., Banla, M., Agla, K., Djagnikpo, P. A., & Gue, K. B. (2004). 
[Knowledge, attitudes and practices regarding glaucoma in the urban and suburban 
population of Lome (Togo)]. Sante, 14(3), 187-191.  
 
Coleman, A. L., & Miglior, S. (2008). Risk Factors for Glaucoma Onset and Progression. 
Survey of Ophthalmology, 53(6, Supplement 1), S3-S10.  
 
Cook, P. F., Bremer, R. W., Ayala, A. J., & Kahook, M. Y. (2010). Feasibility of motivational 
interviewing delivered by a glaucoma educator to improve medication adherence. Clin 
Ophthalmol, 4, 1091-1101.  
 
Giorgis, A. T., Mulugeta, A., Aga, A., & Deyassa, N. (2012). The spectrum of glaucoma 
presentation at Menelik II Hospital, Addis Ababa. Ethiop Med J, 50(3), 259-264.  
 
 132 
Golin, C. E., Earp, J., Tien, H. C., Stewart, P., Porter, C., & Howie, L. (2006). A 2-arm, 
randomized, controlled trial of a motivational interviewing-based intervention to 
improve adherence to antiretroviral therapy (ART) among patients failing or initiating 
ART. J Acquir Immune Defic Syndr, 42(1), 42-51.  
 
Gray, E., McCambridge, J., & Strang, J. (2005). The effectiveness of motivational 
interviewing delivered by youth workers in reducing drinking, cigarette and cannabis 
smoking among young people: quasi-experimental pilot study. Alcohol Alcohol, 40(6), 
535-539. doi: 10.1093/alcalc/agh199 
 
Gyasi, M., Amoako, W., & Adjuik, M. (2010). Presentation patterns of primary open angle 
glaucomas in north eastern ghana. Ghana Med J, 44(1), 25-30.  
 
Kirwan, J. F., Cousens, S. Venter, L., Cook, C., Stulting, A., Roux, P., Murdoch, I., (2006). 
Effect of [beta] radiation on success of glaucoma drainage surgery in South Africa: 
randomised controlled trial. BMJ, 333(7575), 942-947.  
 
Kyari, F., Gudlavalleti, M. V., Sivsubramaniam, S., Gilbert, C. E., Abdull, M. M., 
Entekume, G., & Foster, A. (2009). Prevalence of blindness and visual impairment in 
Nigeria: the National Blindness and Visual Impairment Study. Invest Ophthalmol Vis Sci, 
50(5), 2033-2039. doi: 10.1167/iovs.08-3133 
 
Lane, C., Hood, K., & Rollnick, S. (2008). Teaching motivational interviewing: using role 
play is as effective as using simulated patients. Med Educ, 42(6), 637-644. doi: 
10.1111/j.1365-2923.2007.02990.x 
 
McCambridge, J., & Strang, J. (2004). The efficacy of single-session motivational 
interviewing in reducing drug consumption and perceptions of drug-related risk and 
harm among young people: results from a multi-site cluster randomized trial. Addiction, 
99(1), 39-52.  
 
Moyers, T. B., Martin, T., Manuel, J. K., Hendrickson, S. M., & Miller, W. R. (2005). 
Assessing competence in the use of motivational interviewing. J Subst Abuse Treat, 28(1), 
19-26.  
 
 133 
Ogedegbe, G., Chaplin, W., Schoenthaler, A., Statman, D., Berger, D., Richardson, T.,  
Allegrante, J. P. (2008). A practice-based trial of motivational interviewing and 
adherence in hypertensive African Americans. Am J Hypertens, 21(10), 1137-1143.  
 
Omoti, A. E., Osahon, A. I., & Waziri-Erameh, M. J. (2006). Pattern of presentation of 
primary open-angle glaucoma in Benin City, Nigeria. Trop Doct, 36(2), 97-100. doi: 
10.1258/004947506776593323 [doi] 
 
Racette, L., Wilson, M. R., Zangwill, L. M., Weinreb, R. N., & Sample, P. A. (2003). 
Primary Open-Angle Glaucoma in Blacks: A Review. Survey of Ophthalmology, 48(3), 
295-313.  
 
Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G. P., & 
Mariotti, S. P. (2004). Global data on visual impairment in the year 2002. Bull World 
Health Organ, 82(11), 844-851.  
 
Rollnick S, M. W. (2008). Motivational interview in health care: The Guilford press. 
 
Rubak, S., Sandbaek, A., Lauritzen, T., & Christensen, B. (2005). Motivational 
interviewing: a systematic review and meta-analysis. Br J Gen Pract, 55(513), 305-312.  
 
Rudnicka, A. R., Mt-Isa, S., Owen, C. G., Cook, D. G., & Ashby, D. (2006). Variations in 
primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-
analysis. Invest Ophthalmol Vis Sci, 47(10), 4254-4261. doi: 47/10/4254 [pii] 
 
Smedslund, G., Berg, R. C., Hammerstrom, K. T., Steiro, A., Leiknes, K. A., Dahl, H. M., & 
Karlsen, K. (2011). Motivational interviewing for substance abuse. Cochrane Database 
Syst Rev(5), CD008063.  
 
Tielsch, J. M., Sommer, A., Katz, J., Royall, R. M., Quigley, H. A., & Javitt, J. (1991). Racial 
variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. 
JAMA, 266(3), 369-374.  
 
Vegini, F., Figueiroa Filho, N., Lenci, R. F., Garcia Neto, D., & Susanna Junior, R. (2008). 
Prevalence of open angle glaucoma in accompanying first degree relatives of patients 
with glaucoma. Clinics, 63(3), 329-332.  
 134 
 
Chapter 4: Context of the studies 
 
 
Figure 5:  The new eye clinic in ATBU Teaching Hospital, Bauchi where this study 
was carried out. 
 
 
 
 
Figure 6: Female and male patients waiting to be seen in ATBUTH eye clinic 
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Location of study; catchment population, usual practices for 
glaucoma 
The study was carried out in the Abubakar Tafawa Balewa University Teaching hospital 
in Bauchi town, which is the capital of Bauchi state. The hospital became a teaching 
hospital in 2010, and is one of three tertiary hospitals in the state. The state and parts of 
neighbouring states form the catchment population of the hospital. 
 
Bauchi state is one of Nigeria’s 36 states and is located in the north-eastern region of 
the country. Kano and Jigawa bound it in the north, by Gombe and Yobe in the east, 
Kaduna in the west, and by Plateau states in the south (Figure 3). 
 
 
 
 
Figure 7: Map of Nigeria showing Bauchi state  
 
Population and demography 
Bauchi state has a population of 4,676,465 - (51.88% males). The population structure is 
pyramidal in distribution indicating low life expectancy, high birth rate, and high death 
rate. There are many ethnic groups in the state with many languages, but almost 
everyone speaks Hausa. English is the official medium of communication and is spoken 
widely especially in the capital city. 
 
Administrative, political and economic structure  
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The state is divided administratively into 20 local government areas headed by 
chairpersons assisted by counsellors. All these officers are democratically elected. There 
are also six traditional (emirate) councils headed by emirs who  have a lot of influence 
over their peoples and are greatly respected. 
Nomadic herding and cultivation of groundnuts, beans, corn, and millet are the major 
occupation of the people in most of the rural areas.[220] The women sometimes help in 
the farms or in tending the livestock, milking the cows and selling the milk and other 
farm produce, but mostly they look after the children. Occupations are more varied in 
urban areas. 
 
Health Sources    
The state has three tertiary hospitals, which are located in the two major urban towns, 
Bauchi and Azare. There are 13 other general hospitals in other towns, and 16 health 
centres, 132 maternity clinics and several hundred health posts and dispensaries 
distributed all over the state. There are many private general medical clinics in the state 
but only one private eye clinic located in the state capital. There are about 250 medical 
doctors, six of whom are ophthalmologists, in the two major urban centres. There are 
hundreds of general nurses (42 ophthalmic nurses) and community health workers. 
There are eight optometrists and three opticians.  There are two government hospitals 
and two private clinics offering cataract and glaucoma and other eye surgeries. The fees 
paid by patients for cataract and also for glaucoma surgery range from £30- to £100.  
 
The population often also access traditional eye healers and itinerant couchers (mobile 
traditional healers who treat cataract) for the treatment of their eye problems often with 
disastrous consequences. Couching is quite common and in many areas is the only eye 
service available.  
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Care of glaucoma patients in ATBUTH Bauchi 
 
 
 
Figure 8: The researcher examining a glaucoma patient in ATBUTH eye clinic 
The following published papers describe the usual care in glaucoma patients in ATBUTH 
including how service is delivered to patients, medical, surgical and post operative 
management, the equipment available, and funding. These are:  
1. Glaucoma care at ATBUTH Eye Clinic, Bauchi.  Abdull MM. Community Eye 
Health J. 2014;27(87). 
2. Managing a patient with open-angle glaucoma: a case study; Kyari F, Abdull MM. 
Community Eye Health. 2012;25(79-80):71-2. 
3. Medical treatment of open-angle glaucoma; Kyari F, Abdull M, Kiage D, Ogunro 
A. Community Eye Health. 2012;25(79-80):77-9. 
4. The basics of good postoperative care after glaucoma surgery. Kyari F, Abdull 
MM. Community Eye Health. 2016;29(94):29-31.
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Paper 7: Glaucoma care at ATBUTH Eye Clinic, Bauchi 
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Paper 8: Managing a patient with open-angle glaucoma: a case 
study 
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Paper 9: Medical treatment of open-angle glaucoma 
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Paper 10. The basics of good post operative care after glaucoma 
surgery* 
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* use of sunglasses post surgery or laser therapy is not evidence based 
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Chapter 5: Trial – Primary outcomes Rationale, Aims 
and Objectives of the trial  
 
 
 
Figure 9: Recruitment of patient in progress. Thumb printing on consent sheet to 
indicate consent to participate. 
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Rationale 
 
Glaucoma is a major problem in Africa with the prevalence of blindness being higher 
than in other regions. There are unique factors that make it particular problem in Africa 
including early onset of the disease, an aggressive course, and late presentation on 
account of lack of primary eye care and awareness. Poor facilities and equipment for 
diagnosis and treatment lead to limited treatment options. There is poor acceptance of 
and adherence to treatment and higher risk of surgical or medical treatment failure. 
Some of these factors are not modifiable. For prevention of blindness in glaucoma, 
research has shown that the outlook can be improved via an intervention aimed at 
changing the modifiable factors such as increasing in awareness and encouraging 
behaviour change for acceptance and adherence to treatment and follow up. Many 
techniques and tools have been used around the world to achieve this. But these may not 
necessarily apply in the population being studied where levels of education are low, a 
proportion of the population are very poor,  and where eye care services are often far 
away from communities. Therefore there is a need to develop and test a locally adaptable 
counselling tool and a suitable delivery method. This research therefore aims to develop 
such a tool and test it in a randomised controlled clinical trial.  
 
One of the barriers to access in glaucoma care in Africa is limited availability of 
equipment and thus treatment options are limited. To create more options for the 
patients a suitable reliable and sustainable procedure needed to be identified. Diode 
laser cyclophotoablation fitted these criteria. Although transscleral diode laser 
cyclophotocoagulation has been used in black people around the world, more data were 
needed about the safety and effectiveness of the procedure. This study therefore also 
aimed to   develop a prospective case series of patients undergoing this form of laser 
treatment. 
 
 
Hypothesis  
 
The hypothesis explored in this trial was that patient counselling, delivered by a trained 
glaucoma educator, will increase acceptance of surgery.   
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Aims and Objectives 
Aim   
 
To assess whether a locally adapted counselling intervention about glaucoma and its 
treatment has an impact on acceptance of surgery among glaucoma patients in Bauchi 
state Nigeria. 
 
Specific objectives included in the PhD 
 
1. To determine if a locally adapted counseling intervention has an impact on 
acceptance of surgery in glaucoma patients. 
2. To assess control of IOP in a series of patients treated with diode laser transscleral 
cyclophotoablation (this series includes patients not recruited in trial) 
 
Trial objectives not included in the PhD as data collection and analyses are on 
going: 
1. To determine the impact of counseling intervention on adherence to topical glaucoma 
medication  
2. To determine the impact of counseling intervention on follow-up in treated glaucoma 
patients. 
3. To determine the impact of counseling intervention on IOP control in treated 
patients with moderate/advanced glaucoma. 
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Methods and Results 
As the delivery of the health education / behaviour change intervention was motivational 
interviewing. Before MI sessions could be delivered an interview guide was required 
which was based on available glaucoma leaflets from other places and what patients 
currently know and do about glaucoma, their perceptions of the disease and its 
treatment, and the barriers they faced in accepting and adhering to glaucoma treatment.  
Intervention development 
Several techniques have been used to develop interventions for patient education and to 
create content for counselling. Most have used the existing literature to develop the 
baseline while doing participatory research through focus group discussions  (FGDs) and 
indepth interviews to ascertain patients’ perspectives. Often, FGDs include health care 
providers. Interventions have been developed this way for a range of medical issues or 
chronic disorders such as psoriasis[221], and childhood obesity.[222] The interventions 
aim to develop educational materials such as pamphlets,[223] text messaging for 
hypertension drug adherence,[224] videos or content to guide counselling. Carers are 
often involved because they have great influence on patient management. 
 
METHODS  
Development of the intervention involved three phases: 
Phase 1: Qualitative research 
Phase 2:  A workshop to integrate lay understandings of glaucoma and gaps in 
patient’s knowledge with existing literature in order to develop a locally relevant 
educational draft in the form of an interview guide 
Phase 3: The content of the interview guide was pilot tested among newly diagnosed, 
literate glaucoma patients 
 
Phase 1 
The purpose of the qualitative research was to assess awareness and patients’ 
perceptions of what glaucoma is and how they have managed their problems.  
The interviews were designed to follow the general pattern of the new proposed 
framework for behavioural diagnosis, modified as necessary to ensure all important 
elements were covered, using additional questions used in other studies.[149, 183, 225] 
The methods, participant groups and findings are presented in the paper “Glaucoma, 
“the silent thief of sight”: patients’ perspectives and health seeking behaviour in Bauchi, 
northern Nigeria”. 
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Phase 2: 
A workshop was held to integrate lay understandings of glaucoma with existing 
literature in order to develop a locally relevant counselling draft, called “The silent thief”. 
Participants included health educators from the ATBUTH, the researcher, a social 
scientist and note-taker, ophthalmic nurses, personnel from local radio and TV stations, 
glaucoma patients and their carers and “lay people” without glaucoma. 
 
The researcher gave a short introduction about the challenges of managing glaucoma in 
the locality. Patient education materials about glaucoma from institutions in Nigeria and 
abroad, including some in the local Hausa language developed in another institution, 
were presented for discussion. Participants were asked to analyse the content of the 
existing pamphlets and list the essential information glaucoma patients need to know, 
formulated as a series of questions and answers. The group reviewed the materials and 
summarised their key messages. Then key findings from the FGD and interviews were 
presented and matched with the summaries and modified as appropriate to reflect the 
local levels of literacy and culture. Following an agreement on the content, participants 
were asked to use phraseology and expressions (in the Hausa language) derived from the 
qualitative research to address each of the questions and refine them, with answers 
reflecting the local dialect, including common slang terms to aid understanding.  
 
 
Figure 10: Workshop to design the counseling draft for use in MI sessions. 
Phase 3: 
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In phase three the content of the interview guide was pilot tested among newly 
diagnosed literate glaucoma patients. They were given a copy of the draft to read prior to 
the interview. Twenty interviews were conducted which were recorded and analysed. 
The findings were used to check and amend the language without compromising the 
content or the quality of the draft.  Most patients agreed that one on one counselling 
with a health worker would be the best way to inform them about glaucoma.   
 
Clinicians reviewed the English translation of the draft locally and at LSHTM for content. 
The final version of the counselling guide for use in MI sessions in the trial – The Silent 
Thief - is shown below.  
 
GLAUCOMA COUNSELLING GUIDE FOR MI SESSIONS – The silent thief of sight 
 
What is glaucoma? 
• Glaucoma is a disease that causes damage to the nerve that is responsible for 
transmitting visual impulses from the eye to the brain. Many people do not know 
about the disease. 
What causes glaucoma? 
The cause of glaucoma is mostly not known, but it is known to be more common in the 
following  
• People with family history of the disease 
• People over 40 years old 
• People using glasses for distance vision 
• People with hypertension or diabetes 
• People using steroids 
• Some types of eye trauma 
• Glaucoma is not caused by Black fly, anger or annoyance, cold, firewood smoke, 
dust, wind, excessive crying or evil spirits. Glaucoma is not infectious, so you 
cannot infect people around you. 
 
How does glaucoma cause blindness? 
• The amount of fluid in the eye that maintains the pressure is normally well 
controlled. Sometimes the pressure becomes high and causes damage to the 
nerve of the eye. This damage is what leads to irreversible blindness. 
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Who is affected by glaucoma? 
• Glaucoma can affect people of any age, but it is more common in people over 35 
years of age. 
 
How does glaucoma present? 
• Glaucoma doesn’t usually present with pain except in few cases. 
• There is a gradual constriction of your peripheral vision 
• With time you can only see what is directly ahead of you not to the side 
• You may have blurring of vision later on 
• You may see rainbow pattern around light 
 
Is glaucoma treatable? 
• Glaucoma can be treated to prevent worsening of vision if we present early, but 
lost vision cannot be recovered. 
 
How is glaucoma treated? 
• Using eye drops or tablets. There are different medications (drops or tablets) 
used to treat glaucoma. Once treatment is started it should not be stopped 
except on doctor’s instruction. 
• There is also surgery for controlling glaucoma. Many people are afraid of surgery 
for glaucoma, but there is nothing to fear as the surgery is effective in controlling 
the disease and many people have had successful surgeries that have controlled 
their disease. 
• There is also another type of treatment called LASER, which is also effective in 
controlling the disease. 
 
More on treatment for glaucoma 
• Traditional eye medication and similar treatments do not control glaucoma and 
tend to cause a delay in seeking for treatment, a delay that may lead to blindness. 
Most traditional medicines used have no measure of dose, one medication is used 
for many diseases, and because the native doctors are mostly itinerant, if you 
have a problem you have no one to complain to. In addition to all this, they have 
no equipment to examine your eye. 
• Having eye surgery is cheaper in the long run than using eye drops, because eye 
drops have to be continued for life. 
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• Glaucoma medication is not the type of medication that you use now and get 
immediate relief. It has to be used for a long time to achieve control. You don’t 
stop using your medication because you feel better or you don’t only use your 
medication when you are not feeling better. 
• You are required to continue using your medication even if in your opinion your 
vision is not improving. 
• If you stop your medication, even the little vision you have may be extinguished. 
• You should find ways to remind you to use your medication on time. 
• If you have a problem with the medication, don’t stop using it. Inform your 
doctor who may change it for you. 
• Remember, even if the eye is a non-seeing eye, do not stop instilling your drops. 
Stopping may cause an even worse problem in that eye, such as pain so severe 
that you feel like plucking out the eye.  
 
What will happen if glaucoma is not treated? 
• Untreated glaucoma leads to deterioration in vision and eventually irreversible 
blindness. 
 
How can we avoid blindness from glaucoma? 
• By not missing our regular appointment once we have been diagnosed with 
glaucoma and placed on treatment. 
• By following the instructions of your health worker with regards to regular 
hospital follow up and use of medication. 
• The advantage of discovering glaucoma early is freedom from irreversible 
blindness. 
 
What should one do if diagnosed with glaucoma? 
• Do not miss your regular follow up. 
• Do not skip medication times 
• Do not be afraid to have surgery if it is recommended by your doctor. 
 
Will I continue to use glaucoma medication after surgery for glaucoma? 
• You will have to use medication on the eye till it is healed. Sometimes anti 
glaucoma medication will still continue even after surgery on doctor’s 
instruction. 
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NOTE  
• Early screening can prevent blindness from glaucoma. Therefore visit the nearest 
eye hospital at least once a year. 
• Let improvements in your sight not stop you from continuing your follow up as 
instructed to do. 
• Let problems with health workers not stop you from coming to hospital. If you 
have any problem with a health worker, report to the head of department. 
• Let some other medical problems not stop your medication and follow up. 
• Remember looking after your eye problem will bring you acceptance from your 
family, continuation of your daily activities, and prosperity in your business and 
life dealings.  
• Family and friends will not avoid you because you are not a burden on them if 
you seek treatment for glaucoma. 
• Finally, do not allow glaucoma to kill your dreams and ambition. 
 
Differentiating between glaucoma and cataract to aid early diagnosis and 
treatment of glaucoma before blindness. 
 
There is widespread confusion between glaucoma and cataract in the study area, an 
important difference being that excellent vision can be restored in individuals who are 
cataract blind by an inexpensive operation, which is not the case with vision loss from 
glaucoma. To help their understanding and differentiation of the two conditions, a 
poster was designed to show the differences between the two, which was based on what 
patients with glaucoma and cataract perceive and how their eyes appear to others. The 
poster indicated what patients should do if they noticed that their vision is reducing. It is 
published in the centre of the journal so that it can be detached and used. 
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Paper 11: What is wrong with my vision, and what can I do? 
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Protocol of the trial of adapted motivational interviewing 
 
The following paper gives a detailed description of the methodology and analysis plan for 
the clinical trial of adapted MI, which was designed to improve acceptance of surgery or 
laser among patients with glaucoma attending ATBUTH, Nigeria. 
1. Adapted motivational interviewing to improve the uptake of treatment for 
glaucoma in Nigeria: study protocol for a randomized controlled trial. Abdull 
MM, Gilbert C, McCambridge J, Evans J. Trials. 2014;15(1):149. 
 
 
 
 
 
Figure 11: An interviewer conducting motivational interviewing with a male 
patient in a quiet room in ATBUTH eye clinic 
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Paper 12: Adapted motivational interviewing to improve the 
uptake of treatment for glaucoma in Nigeria: study protocol for 
a randomized controlled trial 
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Chapter 6: Interventions to improve glaucoma 
management 
Results of the randomized clinical trial 
 
The following paper describes the primary outcome of the randomised clinical trial of 
adapted MI to improve the uptake of surgery or laser in the study area. The paper has 
been accepted for publication in Journal of Glaucoma.  
1. Can adapted motivational interviewing to improve the uptake of surgical or laser 
treatment for glaucoma in Nigeria: a randomized controlled trial. Abdull MM, 
McCambridge J, Evans J, Muazu F, Gilbert C. Journal of Glaucoma. In press 
 
 
Figure 12: Home visit to measure a patient’s IOP with a hand held Perkins 
tonometer in her home following tracing after failing her scheduled appointment 
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Paper 13: Can adapted motivational interviewing improve the 
uptake of surgical or laser treatment for glaucoma in Nigeria:  
randomized controlled trial 
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ABSTRACT 
 
Purpose: To assess whether adapted motivational interviewing has any impact on the 
proportion of participants who subsequently underwent surgery or laser treatment for 
glaucoma.  
 
Methods: A single site randomized controlled trial in Bauchi, Nigeria. Participants were 
new patients with a confirmed diagnosis of primary open angle glaucoma in one or both 
eyes, where surgery or laser was recommended. Intervention was a session of 
motivational interviewing adapted for glaucoma and the local context, using an 
interview guide based on local qualitative research. Participants were randomly allocated 
to intervention or usual care. Usual care was routine explanation by an ophthalmologist 
and an educational pamphlet. After the interview, a 12-item Working Alliance Inventory 
questionnaire was administered to patient-interviewer pairs to assess the collaborative 
relationship.  
 
Results: 276 glaucoma patients participated; 70% males. 135 (49%) were assigned to 
adapted motivational interviewing and 141 to usual care. All received the intervention as 
allocated. Uptake (i.e., the proportion who underwent treatment) of laser or surgery in 
the motivational interviewing group was 52% compared with 45% in the usual care 
group (risk difference 7.2%, 95% confidence interval -4.5-18.9%). Mean Working Alliance 
Inventory scores were 68.0 for interviewers and 68.5 for participants with a combined 
reliability coefficient of 93.9% (i.e., high internal consistency and reliability). 
 
Conclusion: We observed only a small increase in the uptake of surgery or laser with 
motivational interviewing compared with usual care which was not statistically 
significant. Although only 1 in 2 patients accepted surgery or laser in this trial, this is a 
much higher proportion than in other studies.  
 
Key words: Glaucoma, Motivational interviewing, Treatment uptake, Africa 
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INTRODUCTION 
Glaucoma is a public health problem in Africa, with the prevalence of blindness due to 
glaucoma higher than in other regions, with an aggressive course,1 2  higher rates among 
young people3, and late presentation4 on account of lack of primary eye care and 
awareness, reduced access to treatment and low awareness of the risk of having primary 
open angle glaucoma (POAG)5.  Health facilities are also poorly equipped6 with 
inadequate human resources and limited treatment options. Exacerbating these 
problems is poor acceptance of and adherence to trabeculectomy, the preferred 
treatment in Africa,7, 8 as patients experience no immediate visual benefit and are fearful 
of the procedure.9 For prevention of blindness in glaucoma there are modifiable factors 
such as increasing awareness by education,10,11 and encouraging change in acceptance 
and adherence to treatment and follow up.  
In this study motivational interviewing (MI) was selected as the intervention to enhance 
uptake of treatment (i.e., they accept and actually undergo treatment).  Motivational 
interviewing has been described as “a collaborative, goal-oriented style of 
communication with particular attention to the language of change. It is designed to 
strengthen personal motivation for and commitment to a specific goal by eliciting and 
exploring the person’s own reasons for change within an atmosphere of acceptance and 
compassion”.12  Guidance includes giving information whilst honouring patient 
autonomy. Motivational interviewing was originally developed for addictive behaviours,13 
and a wide range of applications have been developed.12  
In this study MI was adapted as an approach to counselling for use in patients with 
glaucoma, and hereafter is referred to as adapted motivational interviewing for glaucoma 
(AMIG). The purpose of the trial was to assess whether AMIG has an impact on the 
uptake of surgery or laser treatment by glaucoma patients. The hypothesis tested was 
that AMIG increases the uptake of treatment (surgery or laser treatment) among 
glaucoma patients in comparison with enhanced usual care.  
 
Setting 
The trial was undertaken in the eye clinic of Abubakar Tafawa Balewa University 
Teaching Hospital (ATBUTH), Bauchi State, in the North East of Nigeria. More than 80% 
of the catchment population of approximately four million people live in rural areas or 
live on less than one United States Dollar (USD) per day, with low levels of literacy 
(males 53%, females 13%).14 All new patients attending the ATBUTH eye clinic are 
allocated a unique medical record number and are given a green registration card, which 
includes the dates of clinic attendance, registration and surgical appointments. Surgery 
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is performed twice a week, and if lists are cancelled in advance patients are notified and 
given another date to attend. It is extremely rare for patients to attend for surgery on any 
date other than the date given. All operations are recorded in the operating theatre 
register, giving details of their name, age, sex, hospital record number and surgical 
procedure. A register of all new glaucoma patients was initiated before the trial started. 
 
METHODS 
 
The definition of POAG used in the trial followed that recommended by Foster in 200215 
which has been applied to normative data from the Nigeria National Blindness and Low 
Vision Survey.16 The values which defined glaucoma were IOP greater than 26mmHg 
(the 97.5th percentile for IOP from the Nigeria Blindness Survey), and a vertical cup disc 
ratio (VCDR) of more than 0.7 (the 97.5th percentile for VCDR from the Nigeria 
Blindness Survey) with visual field loss consistent with glaucoma in one or both eyes.  
 
Trial design  
This was a single site effectiveness trial with 1:1 allocation to evaluated intervention or 
enhanced usual care.17 No changes were made to the protocol after the trial started. The 
trial is reported in accordance with the CONSORT statement.18,19 The full protocol has 
been published and can be assessed at 
http://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-15-149. The trial is 
registered at Controlled-Trials.com, registration number ISRCTN79330571, available at 
the following URL. 
http://www.isrctn.com/ISRCTN79330571?q=abdull&filters=&sort=&offset=1&totalResults
=1&page=1&pageSize=10&searchType=basic-search. 
 
Inclusion criteria: New patients (i.e., first attendance at ATBUTH) with a confirmed 
diagnosis of POAG in one or both eyes, where surgery or laser was recommended as the 
treatment of choice to preserve vision. The surgeon decided which eye was most in need 
of urgent treatment. Other inclusion criteria included aged 17 years or above, ability to 
understand Hausa or English and lived within 200 km of the clinic. 
 
Exclusion criteria: Patients who had ocular comorbidities or systemic diseases that may 
contraindicate surgery or laser, communication problems such as profound deafness, 
previous ocular surgery (except cataract surgery), specific referral for glaucoma surgery, 
or lack of consent to participate. 
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Intervention   
The intervention was a single session of MI adapted for the local context and language 
using a draft interview guide generated following a qualitative study.9 The principal 
researcher was trained in MI in Europe in two workshops and subsequently coached the 
two study interviewers. They worked together in pilot interviews until a satisfactory level 
of competence had been reached. The interviewers conducted all the interviews in a 
quiet room in the clinic, in the participant’s preferred language (Hausa or English). The 
interviewer engaged the participant by presenting an agenda for discussion which 
included awareness of glaucoma and the consequences of no treatment, acceptance of 
surgical treatment options, adherence to prescribed medication and follow up to 
monitor the eye pressure. Open-ended questions were asked, with active listening 
including reflections. The interviewers sought to understand the participant’s 
perspective in an empathic fashion and listened for evidence of change talk.  
 
Fidelity to MI (whether delivery adheres closely to the approach) can be assessed using 
the Motivational Interviewing Treatment Integrity code (MITI).20 The extent to which a 
collaborative relationship forms between interviewer and client is assessed using the 
Working Alliance Inventory (WAI)21 and high WAI scores given by interviewers and 
clients indicate greater connection between the two parties. The AMIG sessions sought 
to follow the spirit of MI, and were recorded. Interview sessions lasted 35 to 60 minutes. 
After the AMIG interview, the 12-item WAI Short Questionnaire (WAI-SR) was 
administered to each participant and interviewer to assess the collaborative 
relationship.21  
 
Outcomes  
The primary outcome was the proportion of participants who accepted and underwent 
surgery or laser treatment (i.e., uptake) within two months of the date given for the 
procedure.  
 
Sample Size  
The sample size was calculated based on the primary outcome using the SAMPSI 
command in Stata 14 statistical software (Stata/IC14.0; Stata Corp, College Station, TX, 
USA). Based on the pilot study, we anticipated that 35% of people in the control group 
would accept and undergo surgery or laser treatment within two months. A sample size 
of 137 in each arm was required to detect a 50% relative or 17.5% absolute increase in 
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uptake (equivalent to an uptake of 52.5% in the intervention group) (power 0.8, alpha 
0.05). The sample size of 137 was rounded up to 150 in each arm to allow for loss to 
follow-up. No subgroup or interim analyses were planned. 
 
Recruitment 
Eligible patients were identified for enrolment by the ophthalmologists who referred 
them to the Project Manager for recruitment. The Project Manager ensured that 
potential participants understood the information sheet and signed the consent form. 
They were given a unique study ID and demographic information, home address and 
telephone number collected to enable subsequent tracing.  
All participants were given a red card with their name, hospital medical record number 
and their trial ID. They were instructed to present this card to the Project Manager at 
every attendance at the clinic, and on presentation they were fast tracked through the 
system. Clinical examination, treatment recommendation, randomization, data 
collection and entry into the trial database were all undertaken on the same day.  
 
Randomisation 
Sequence generation: A statistician, not at the project site, generated the randomization 
list using the randbetween function in Excel (Office 2013, Microsoft inc). Block 
randomization with variable block sizes was used to ensure balance in the groups over 
time, as the uptake of laser or surgery may fluctuate over time.  
 
Allocation concealment mechanism: The option of AMIG or no AMIG was printed on 
headed paper, signed and stamped off-site, in London by persons not involved in the 
trial. These were placed in sequentially numbered opaque envelopes in accordance with 
the randomization schedule, which were then sealed and stamped. A second similar 
procedure was followed to randomize those allocated to AMIG to either interviewer A or 
interviewer B. These envelopes were kept in a locked cupboard and were only opened 
when needed. 
 
Implementation:  Immediately after recruitment the next envelope in the sequence was 
opened to see if the patient was allocated to AMIG or not. The interviewers wrote the 
sequence number on the participant’s form and their unique ID number was written on 
the outside of the envelope and returned to a sealed locked container. The same 
processes were adopted for allocation to interviewer A or B. 
 
  194 
Procedures 
During the clinical consultation with the attending ophthalmologist before 
randomization, an explanation of glaucoma was given to all participants as well as the 
treatment options and prognosis.22 After explaining treatment options the 
ophthalmologist recommended one form of treatment, taking account of the severity of 
disease and socio-demographic variables. Usual care was enhanced by providing all 
participants in both groups with written information, in Hausa or English, about 
glaucoma. This written information was developed and pilot tested following interviews 
with glaucoma patients. The pamphlet, which was called the “Silent Thief”, contained 
images to represent visual field loss and conveyed simple messages. A copy of the 
pamphlet was also displayed at the entrance to the clinic. 
The date for surgery or laser was determined at the first consultation and name, age, sex, 
hospital medical record and procedure were entered into the operating list. Patients 
were informed of the date orally and it was written on their red card. The date and type 
of surgery were recorded in the database. A separate tracing database was created 
containing the agreed date of surgery for each participant and a date two months after 
this date was generated automatically.    
Severity of glaucoma in the study eye was categorized as early, moderate, advanced or 
end stage, based on VCDR and visual field loss. The former was assessed subjectively by 
the ophthalmologist using direct or indirect ophthalmoscopy or with fundus 
photography with a DRS digital fundus camera (CentreVue SpA Padova, Italy). Visual 
fields were assessed using an Oculus Twinfield Visual field analyser (OCULUS 
Optikgeräte GmbH). Early glaucoma was defined as VCDR of less than 0.8 with very 
little to no visual field loss, moderate as a VCDR less than 0.8 with a visual field greater 
than 10 degrees, advanced as a VCDR of 0.8-0.9 with a visual field of approximately 5-10 
degrees and end stage was defined as a VCDR of 1.0, with a visual field of 5 degrees or 
less, including when no visual field could be recorded.  
 
Ascertainment of the primary outcome 
Every operating day the operating list was checked by the Project Manager to ascertain 
whether trial participants had attended for laser or surgery on the day allocated, by cross 
checking details in the operating book with those in the trial database. For those 
attending, the date and type of treatment  performed were recorded. Participants who 
did not attend on the date allocated but who attended within the two month period 
were identified by presentation of their red cards to the Project Manager. 
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Masking 
Only participants allocated to AMIG and the AMIG interviewers knew who had been 
allocated to AMIG. Participants were asked by the interviewers not to discuss whether 
they had had an interview with the Project Manager, ophthalmologists or other patients 
to avoid contamination and to maintain masking. In particular, the Project Manager, 
who was responsible for assessing the primary outcome, was masked to the treatment 
allocation.  
 
Data management 
Two databases were created in Epidata (EpiData Odense Denmark, EpiData Association, 
2010-. Http://www.epidata.dk) with range and consistency checks. The Project Manager 
entered data into the main trial database. Data were entered as soon as possible after 
recruitment, so that the ‘surgery date’ and ‘tracing date’ outputs could be generated. All 
data entries were double-checked by the lead researcher (MA). The second database, 
which was maintained by the interviewers, contained the unique ID, allocation status for 
AMIG and interviewer, and WAI data. The databases were maintained on separate 
password projected computers in different lockable offices. Random checks of the 
quality of data entry were regularly performed in Stata (Stata/IC14.0; Stata Corp, College 
Station, TX, USA).  
 
Data analyses 
The randomization code was broken only after analysis of the primary outcome, which 
was by intention to treat. There were no missing data on the primary outcome. We 
compared the proportion of people in the intervention and control group achieving the 
primary outcome (uptake of surgery or laser treatment) using  the risk ratio and the risk 
difference and report these two measures of effect with 95% confidence intervals 
(calculated using the ‘epitab’ command in Stata 14). Univariate and multivariable logistic 
regression analyses were performed to explore factors associated with undergoing 
surgery or laser treatment such as gender, age group, distance to hospital, education, 
occupation, mode of presentation, severity of disease, baseline IOP and interviewer. 
Analysis by interviewer was performed to explore whether the primary outcome varied 
with the interviewer performing AMIG. Post-hoc analysis of the primary outcome and 
WAI data was undertaken to compare outcomes and quality of the earlier and later 
AMIG interviews (first half versus second half).  
 
  196 
Working Alliance Inventory questionnaires for participants’ and interviewers’ ratings of 
the AMIG sessions were analyzed as total WAI scores and medians. Cronbach's alpha 
test was applied to participant and interviewer total scores to assess the level of 
correlation between scores. Data were also analysed to assess whether WAI scores for 
participants, and for interviewers, were associated with the primary outcome using 
median split WAI scores using Pearson chi square test.  
 
RESULTS 
 
Recruitment was slower than anticipated due to civil unrest in North Eastern Nigeria 
(September 2013 to September 2015). Only one eligible patient refused to participate 
(Figure 1). A total of 276 glaucoma patients participated in the study. 135 (49%) were 
assigned to the intervention group and 141 to the control group. All received the 
intervention as allocated. There were no major imbalances between the two groups at 
baseline (Table 1).  
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Table 1. Baseline socio-demographic and ocular variables, by allocation arm 
 
  
AMIG* 
n=135 No AMIG n=141 Total n=276 
  % (n) % (n) % (n) 
Gender Male 71% (96) 68% (96) 70% (192) 
  Female 29% (39) 32% (45) 30% (84) 
Age group 16-30 years 12% (16) 9% (12) 10% (28) 
  31-50 years 39% (53) 34% (48) 37% (101) 
  51-70 years 44% (59) 46% (65) 45% (124) 
  >71 years 5% (7) 11% (16) 8% (23) 
Education None 17% (23) 18% (26) 18% (49) 
  Primary/secondary school 36% (48) 26% (37) 31% (85) 
  Graduate/post graduate 27% (36) 33% (47) 30% (83) 
  Informal schooling 20% (27) 22% (31) 21% (58) 
  Missing 1% (1) 0% (0) 0% 
Distance to  ≤10 km 65% (88) 52% (73) 58% (161) 
clinic >10-100km 13% (18) 24% (34) 19% (52) 
  >100 17% (23) 22% (31) 20% (54) 
  Missing 4% (6) 2% (3) 3% (9) 
Ocular variables None/early 7% (10) 12% (17) 10% (27) 
POAG severity Moderate 16% (21) 16% (23) 16% (44) 
  Advanced 47% (63) 37% (52) 42% (115) 
 End stage 29% (39) 33% (47) 31% (86) 
 Missing 2% (3) 1% (2) 2% (5) 
Presenting 
visual acuity 
≥20/60 32% (43) 24% (34) 28% (77) 
<20/60-20/400 30% (41) 38% (53) 34% (94) 
  <20/400 37% (50) 38% (53) 37% (103) 
 Missing 1% (2) 1% (1) 1% (3) 
Presenting IOP Normal <21 mmHg* 13% (17) 10% (14) 11% (31) 
  High 21-40 mmHg 52% (70) 60% (85) 56% (155) 
  Very high >41 mmHg 33% (45) 28% (40) 31% (85) 
  Missing 2% (3) 1% (2) 2% (5) 
Treatment 
recommended at 
recruitment 
Laser cyclophotoablation 93% (131) 84% (114) 89% (245) 
Trabeculectomy 5% (7) 10% (13) 7% (20) 
Trabec. + cataract surgery 1% (1) 3% (4) 2% (5) 
Laser trabeculoplasty 0% (0) 1% (2) 1% (2) 
Laser + cataract surgery 0% (0) 1% (1) 0% (1) 
Missing 1% (1) 1% (1) 1% (3) 
TOTAL   100% (135) 100% (141) 100% (276) 
*AMIG- Adapted motivational interview for glaucoma 
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In almost all patients (89% of the 276 participants) laser treatment was recommended, in 
7% glaucoma surgery alone was recommended and in 4% a combination of cataract 
surgery with trabeculectomy or laser was recommended. Slightly more of the 
intervention group (93%) were recommended laser compared with the control group 
(84%) but this difference was not statistically significant.  When participants attended 
for treatment they were administered the treatment they preferred. All 133 treated 
patients underwent laser treatment by choice which was the treatment recommended in 
all but 13. 
 
 
 
Figure 1: Participant flow diagram showing enrolment of participants 
 
 
Outcomes  
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Primary outcome 
Uptake of treatment in the AMIG group was 52% compared with 45% in the usual care 
group (Table 2). The risk ratio was 1.2 (95% confidence interval (CI) 0.9-1.5) and the risk 
difference was 7.2% (95% CI 0-18.9%).   
 
 
Table 2: Results of primary outcome of the trial, uptake of surgery or laser 
 
Acceptance AMIG* No AMIG Total 
  % (n) % (n) % (n) 
Underwent laser or surgery 52% (70) 45% (63) 48% (133) 
Did not undergo laser or surgery 48% (65) 55% (78) 52% (143) 
Total 100% (135) 100% (141) 100% (276) 
*AMIG – Adapted motivational interviewing for glaucoma 
 
 
The number of participants allocated to interviewer A was 68 and 67 to interviewer B. 
There was no significant difference in the uptake of treatment between interviewer A 
and interviewer B, being 46% for interviewer A and 54% for interviewer B (Pearson 
chi2(1): 0.9073; p = 0.34).  
 
In the first 138 patients recruited (of the 276 total) the risk ratio was 1.1 (95% CI 0.8-1.5) 
and the risk difference was 2.8% (95% CI -13.8-19.5%). In the last 138 recruited the risk 
ratio was 1.3 (95% CI 0.9-1.8) and the risk difference was 11.3% (95% CI -5.2-27.9%). There 
were no differences in interviewer and participant median WAI scores during the two 
time periods (69% and 71% vs 69% and 71% respectively). 
 
In univariate analysis, participants with either graduate/post graduate or informal 
education were more likely to undergo treatment than and those with no education 
(Pearson ch2, 15.16, p = 0.01). There were no other statistically significant predictors of 
uptake of treatment by socio-demographic or ocular variables in the univariate analyses. 
Education was also strongly predictive in the multivariable analysis (Table 3). 
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Table 3: Multivariable logistic regression analysis of factors affecting uptake of surgery or 
laser 
 
  Uptake  n Odds Ratio 
[95% Confidence 
Interval P value 
Intervention No AMIG 141 Ref   
 AMIG 135 1.60 0.91 - 2.81 0.10 
Socio-demographic variables     
Gender Male 192 Ref   
 Female 84 1.92 0.83 - 4.47 0.13 
Age group 16-30 years 28 Ref   
 31-50 years 101 4.20 1.22 - 14.44 0.02 
  51-70 years 124 3.09 0.90 - 10.64 0.07 
  >71 years 23 3.65 0.75 -17.63 0.11 
Occupation Unemployed/housewife 39 Ref   
 Professional 36 0.15 0.04 - 0.60 0.01 
  Worker/labourer 50 0.55 0.16 - 1.95 0.36 
  Trader 29 1.59 0.45 - 5.62 0.47 
  Retired 83 0.50 0.16 - 1.52 0.22 
  Student 16 0.27 0.05 - 1.57 0.15 
 Other 23 0.52 0.13 - 2.17 0.37 
 Distance from  <10km 161 Ref   
home to hospital >10-100km   52 1.57 0.72 - 0.43 0.26 
>100 54 0.76 0.35 - 1.62 0.47 
 Missing 9    
Education No formal education 49 Ref Missing data  
 Informal schooling  85 5.70 2.15 - 15.10 <0.001 
 
Primary/secondary 
school 83 4.62 1.60 - 13.32 0.01 
  Grad/post grad 58 9.44 2.97 - 30.04 0.00 
 Missing 1    
Ocular variables      
Visual acuity >20/60 77 Ref   
 <20/60-20/400  94 0.59 0.26 - 1.31 0.19 
  <20/400  103 0.51 0.18 - 1.44 0.20 
 Missing 2    
POAG severity Early 27 Ref   
 Moderate 44 0.81 0.28 - 2.32 0.69 
  Advanced 115 1.52 0.55 - 4.25 0.42 
  End stage 86 2.42 0.66 - 8.92 0.18 
 Missing 4    
IOP group Normal 31 Ref   
 High 21-40 mmHg 155 3.29 1.20 - 8.98 0.02 
 Very high >41 mmHg 85 2.94 0.97 - 8.91 0.06 
  Missing 5    
AMIG= Adapted motivational interviewing for glaucoma 
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In the adjusted analysis (Table 3) the odds ratio for undergoing treatment was 1.6 (95% 
CI 0.9-2.8) but this was not statistically significant.  
Fidelity testing using MITI for English language sessions was planned, but was not 
possible because all interviews were conducted in local languages, Hausa or Pidgin 
English, which prevented formal coding.   
Analysis of Working Alliance Inventory scores 
Analysis of WAI showed similar scores for participants and interviewers overall and were 
similar for both interviewers (Table 4).   
 
Table 4: Correlation between participant and interviewer Working Alliance Inventory 
scores  
 
  Mean WAI score 
WAI interviewers (n=132) 68.0 (range 45-74; SD 5.06) 
WAI patients (n=135) 68.5 (range 42-78; SD 5.16) 
WAI interviewer A (n=66) 67.3 (range 45-73; SD 5.53) 
WAI interviewer B (n=66)   68.6 (range 52-74 SD 4.49) 
Cronbach's alpha patient and interviewer total scores  
Test scale = mean (unstandardized items)  
Average inter-item covariance 23.13 
Number of items in the scale 2 
Scale reliability coefficient 93.9% 
Cronbach's alpha interviewer   
Test scale = mean (unstandardized items)  
Average inter-item covariance 0.25 
Number of items in the scale 12 
Scale reliability coefficient 94.3% 
Cronbach's alpha patient   
Test scale = mean(unstandardized items)  
Average inter-item covariance 0.21 
Number of items in the scale 12 
Scale reliability coefficient 93.3% 
WAI = Working Alliance Inventory.  SD = standard deviation 
 
Analysis of WAI scores gave the same median split for participant and interviewer scores 
overall (median scores 70 for both). There were no statistically significant differences in 
the primary outcome by interviewer median split WAI scores.  
 
There were no harmful or unintended effects in either group. 
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DISCUSSION 
 
Participants in the AMIG arm underwent treatment at a higher rate than the usual care 
group (a difference of approximately 7%) but this difference could have arisen by chance. 
This is the first trial to use this counselling intervention for glaucoma in Africa, and the 
results do not support introduction of adapted MI into routine practice.  
 
The sample size calculation was based on a pilot study of 45 individuals in which there 
was an absolute difference of 12% between AMIG (47% uptake) and usual care (35% 
uptake) groups, but a difference of this magnitude may have occurred by chance as the 
sample size was small.17 In the main trial the observed risk difference does not exclude 
the possibility of a 19% difference. There was no difference in uptake of treatment by 
interviewer, which reflects the similarities in WAI scores.  
 
In this trial all participants underwent laser treatment, which was described as 
“computer light treatment”, probably because this term induces less fear than the term 
surgery.4 Laser treatment also does not require an inpatient stay, so reducing patient 
costs. Indeed, uptake of treatment for glaucoma has improved dramatically since laser 
treatment became available:  six years prior to the trial, when laser was not available, 
only 8% of 85 glaucoma patients offered surgery as the treatment of choice agreed to the 
procedure, and less than 2% finally underwent surgery4. Participants who underwent 
laser treatment in the trial may also have discussed their experiences with friends, family 
and community members, which increased the acceptability of laser treatment amongst 
those who subsequently attended the clinic, regardless of allocation. Other reasons for 
the higher than anticipated uptake of laser treatment in the usual care group could 
reflect improvements in the infrastructure, equipment, skills and motivation of trained 
staff since the pilot study, and the more informative educational pamphlet given to all 
participants.  
 
Cultural factors are relevant to the interpretation of these findings. Uptake of treatment 
was higher among participants with higher levels of education, as has been shown 
previously.23 However, uptake was not associated with severity of disease, even amongst 
those at imminent risk of blindness. The reason for this finding is not clear, as it is not 
uncommon for patients with advanced or end stage disease to lose hope, as highlighted 
in our earlier study.9 Professionals, despite their higher level of education, had lower 
uptake of surgery or laser, which may reflect lack or time or a preference for topical 
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treatment, which they can afford.   
 
We have no data on fidelity to MI, which if low, may also explain the lack of effect. 
Motivational interviewing is complex and may require more and better training and 
supervision than was possible in this effectiveness trial.24 The WAI data were not subject 
to linguistic restrictions, and the results showed encouragingly good concordance, 
although these self-reported data are subject to information bias. 
Follow up of participants for treatment and research purposes continues to be a major 
challenge in rural Africa where many glaucoma patients never return after the first visit. 
Low cost approaches such as text message reminders, that have been used to improve 
follow up in trabeculectomy patients, may be employed.25 
The findings of this trial may be generalisable to other clinics that treat patients with 
glaucoma in this area, and potentially also elsewhere in Africa. However, it may not be 
generalisable to the general population where there will be many more people with 
undiagnosed, earlier glaucoma who may react differently to AMIG.  
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Chapter 7: Transcleral Diode Laser 
Cyclophotocoagulation case series  
Transscleral diode laser cyclophotocoagulation has only been used in the management of 
refractory glaucoma until recently when its use has been extended to seeing eyes with 
glaucoma even as primary treatment.[79, 107, 113] Cyclodiode is effective for all types of 
glaucoma and can be carried out with few complications compared with traditional 
surgery. The effect can decline over time but it can be safely repeated. It is easy to teach 
and easy to learn. In facilities where cost is a major concern, it is a cost effective option 
as the laser can also be used to treat other conditions such as diabetic retinopathy, sickle 
cell disease, central retinal vein occlusion and retinopathy of prematurity. The initial 
cost outlay may be high but it is still much cheaper than other lasers, such as argon, and 
it requires little to no maintenance. The diode laser is small and portable, and can be 
transported with ease to treat patients even in outreach centres. 
 
Current studies in seeing eyes have demonstrated the effectiveness of the laser in 
adequately controlling intraocular pressure and preserving vision in seeing patients. In 
patients with blind painful eye from refractory glaucomas such as neovascular glaucoma, 
it is very effective in providing pain relief. As it is an extraocular procedure, the risk of 
complications that are inherent in other incisional surgical glaucoma treatments is very 
low, as such it is good in areas where patient follow up is poor. 
The following paper describes the findings from a pilot study of a cohort of patients with 
advanced glaucoma but with remaining vision who have been treated with cyclodiode as 
primary treatment.  The data presented is the largest prospective series of African 
patients with seeing eyes treated with cyclodiode.  
The source of the patients for this case series was patients attending the study hospital 
whether as primary patients or as patients referred from other neighbouring centres with 
or without a diagnosis of glaucoma. This case series includes glaucoma patients who 
were not part of the trial either because they were not eligible for the trial, were treated 
before recruitment started or after recruitment for the trial had ended. Details of the 
study are in the paper submitted for publication below. 
 
1. Trans-scleral diode laser cyclophotoablation an alternative treatment for primary 
open angle glaucoma in black populations.  Abdull MM, Evans J, Broadway D, 
Kyari F, Muazu F, Gilbert C. 
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Figure 13: Transscleral diode laser cyclophotocoagulation in progress 
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Paper 14: Trans-scleral diode laser cyclophotoablation an 
alternative treatment for primary open angle glaucoma in black 
populations 
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ABSTRACT   
Purpose 
In Africa patients with glaucoma present very late, have poor medication adherence, low 
acceptance of trabeculectomy and poor follow-up. This study explored the safety and 
effectiveness of transscleral diode laser cyclophotocoagulation as a primary treatment for 
sighted eyes with primary open angle glaucoma.  
Methods 
Prospective case series of new patients with a presenting acuity ≥3/60 where surgical 
intervention was recommended. A diode 810nm laser G-probe was used under 
retrobulbar anaesthesia to deliver approximately 20 shots for 2000ms, titrating the 
power on an individual basis. A second treatment was offered if the IOP was high 
(>21mmHg) on two consecutive visits. Main outcomes among first eyes treated:  IOP of 
<22mmHg, change in ≥2 lines of Snellen acuity at 12 months, complications.  
Results 
17/204 (8.3%) first eyes treated had a second treatment. Mean age was 52 years, 69% 
were male. 107 (52.5%) attended at 12-months. Before treatment (202 eyes with data) 
mean IOP was 39 (SD11) mmHg being 12, 11, 15, 18, 19 and 19mmHg on day one, one week, 
and 1, 4, 6 and 12 months respectively. At 12 months 77 (72.6%) eyes (106/107 with data) 
had IOPs <22mmHg. At 12 months 83 (78 %) eyes retained (70 eyes,  66%) or had 
improved ( 13  eyes,  12%) visual acuity; 25 eyes (  23%) lost acuity. Post-operative 
complications included mild, transient uveitis (5.9%), corneal oedema (2.2%), severe 
uveitis (0.5%), and transient hypotony (2.2%). Eyes treated twice had slightly higher 
complication rates. At 12 months no eyes had persistent hypotony.  
Conclusions 
Diode laser was effective in controlling IOP in almost three quarters of eyes at 12 months 
with short-term preservation of vision and minimal complications. Poor follow-up 
highlights the need for an effective, safe and acceptable treatment where regular follow 
up is less critical.  
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INTRODUCTION 
 
Africa is the region with the highest prevalence of primary open angle glaucoma (POAG) 
affecting an estimated 7 million people aged 40-80 years.1 The predisposition to POAG in 
Africa is likely due to variation in genetic susceptibility.2 Furthermore, glaucoma is 
responsible for a higher proportion of blindness in Africa than in other regions (range 8-
22.9%)3,4 5 being 16.3% in Nigerian adults aged 40 years and above.6  
 
Glaucoma is more blinding in Africa than in other regions as it has an earlier age of 
onset7 with a longer life time risk of blindness. For example, in a study in the United 
States of America glaucoma began 10 years earlier in people of African descent than in 
Caucasians and was 6.6 times more frequent.8 In individuals of African descent, 
glaucoma also has a more aggressive course,9 which increases the lifetime risk of 
blindness. In Africa, most people with glaucoma present very late, often already blind in 
one eye10 11 and there is poor awareness of the disease.12 13 Services for eye care, 
particularly for primary eye care and for specialist glaucoma care, are inadequate with 
the latter being mainly located in major urban centres.14 15 A high proportion of the 
population are poor and cannot afford the cost of treatment or follow up.16 In addition, 
adherence to systemic or topical medication is often low11 17 as is acceptance of glaucoma 
surgery since this does not improve visual function,11 and patients are fearful of 
undergoing surgery on their only seeing eye. Even though trabeculectomy can provide 
stable and long term IOP control in people of African origin,18 ophthalmologists in Africa 
19are often reluctant to offer trabeculectomy for fear of complications, including visual 
field “wipe-out” in advanced cases20 and the known variable outcomes in Africa.21-25 
 
There are only a few studies comparing the outcome of surgical interventions for 
glaucoma in patients of African descent, including laser procedures.26 27 In a recent 
review, the authors concluded that there was no evidence that any procedures are 
superior to trabeculectomy in eyes of patients of African descent, and there is compelling 
evidence that the outcomes of trabeculectomy are less good than for Caucasian eyes, 
particularly if antimetabolites are not used.28 Given the relatively low uptake of surgery, 
poor outcomes and inadequate follow up, laser treatment could be considered as a 
primary treatment for glaucoma in Africa despite the limited reported evidence. 
 
In our pilot study, we chose transcleral diode laser cyclophotocoagulation (TDLC) as the 
modality of choice given the ease of delivery, the relatively low cost of the laser and 
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accessories, together with low maintenance costs. Diode lasers can also be used for a 
range of other eye conditions so lowering unit costs and hence costs to patients. All 
these factors make may make TDLC a feasible and scalable option, particularly in low-
income settings with very few glaucoma specialists. 
 
In a published review of 18 studies of TDLC treatment, the number of eyes treated 
ranged from 8 to 263, and follow up ranged from 9 to 66 months.29 The studies had 
different indications for treatment and often included different types of glaucoma. The 
proportion of eyes in which intraocular (IOP) was controlled (i.e. <22mmHg) ranged 
from 38% to 88.1% (in 13 studies reporting this outcome).29 There are only a few studies 
of TDLC for seeing eyes, or as a primary treatment, or which were undertaken in Africa.  
 
With respect to studies on seeing eyes (Table 1A and 1B), in a retrospective study in the 
UK, the indication for treatment was uncontrolled glaucoma on maximal medical 
treatment: among the 46 eyes treated, 52% had POAG, the mean pre-treatment IOP was 
24 (12-35mmHg) and at 2 years 80% of eyes had an IOP of <22mmHg with or without 
additional topical treatment: 23.9% of eyes lost more than two lines of VA30. In another 
UK study, 49 seeing eyes were treated for uncontrolled glaucoma and at five years IOP 
was controlled (6-21mmHg) in 79.6% of eyes; 30.6% lost ≥2 lines of VA.31  
 
Primary treatment for glaucoma using TDLC has been reported in several studies, most 
of which are prospective or retrospective case series (Table 1A and 1B). For example, a 
study in Germany recruited individuals who refused surgery or where follow up could 
not be guaranteed: among the 25 eyes treated, retreatment was required in 3 eyes.32 In 
another study of primary treatment for a range of different types of glaucoma in 
Germany, 193 eyes were treated: at follow up 90% of eyes with POAG had IOPs of 10-
22mmHg after single or multiple treatments.33    
There are only four studies reporting TDLC treatment outcomes in Africa, from 
Cameroon,34 Malawi,35 Ghana36 and Tanzania,37 which had different indications for 
treatment, varying outcomes, small sample sizes and poor follow up.  
 
TDLC laser treatment is relatively safe, with mild anterior uveitis immediately after 
treatment being the commonest complication reported (Table 1). The reported 
complications of TDLC include mild anterior uveitis following the treatment. Other less 
common complications reported following TDLC include conjunctival or scleral burns, 
hyphaema, atonic pupil, choroidal detachment and hypotony, which in some cases are 
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related to decreased vision following the treatment. Table 1 presents the complications 
leading to the reduced vision identified in some studies. Most of the more serious 
complications were in studies which included patients with intractable or complex 
glaucoma. 
Tables 1A and 1B 
The purpose of this prospective pilot study was to explore the safety and effectiveness of 
TDLC treatment for POAG in the seeing eyes of African patients with POAG. The study 
was undertaken in a tertiary level eye department in north-east Nigeria.  
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Table 1A. Transscleral diode laser cyclophotocoagulation treatment studies: indications for and methods of treatment, 
participants and outcome measures 
Author, 
country (ref) Study design Type of glaucoma Indications for treatment 
Number 
treated 
Definition of 
outcome 
Preoperative IOP 
(mmHg) (range) 
Studies in Africa  
Egbert, 
Ghana41 
Trial of laser 
power 
POAG Primary treatment 92 eyes Final IOP <22 mm 
Hg 
Mean 29.3 (16-
66)mmHg 
Mavrakanas, 
Tanzania36 
CS - 
retrospective 
POAG (seeing and 
non seeing) 
Uncontrolled IOP 49 eyes Lower IOP Mean 53mmHg 
Preussner, 
Cameroon33 
CS - prospective 
using 910nm 
laser  
POAG IOP reduction; reduction in 
medication  
272 eyes; 26 
followed up 
IOP reduction at 1 
year 
Mean 31.2mmHg 
Schulze, 
Malawi34 
CS - prospective POAG; PXE  IOP reduction 47 eyes Mean IOP 
reduction 
Mean 38.5mmHg 
Studies in other countries  
Rotchford, 
UK30 
CS - 
retrospective  
POAG seeing eyes Primary treatment 49 eyes Loss of 2 or more 
VA line IOP 8-21 
28mmHg (16-50) 
Ghosh, UK29 CS - prospective POAG seeing eyes High IOP 
 
46 eyes 24 months follow 
up 
Mean 24mmHg 
Kuchar, USA42 CS - prospective 
(micropulse 
laser) 
Advanced  Uncontrolled IOP 19 eyes 6-21 mmHg/20% 
lower at last visit  
Mean 37.9 mmHg  
Butt, Pakistan40  Quasi-
experimental  
POAG  POAG on maximum 
medication; Primary Rx 
60 eyes IOP reduction  Mean 41.62 (28 – 60) 
mm Hg 
Bloom, UK43  CS - prospective. 
YAG laser 
Any type Refractory glaucoma after 
multiple procedures 
45 eyes Not defined Mean 32mmHg 
Ansari, UK44 CS - 
retrospective 
Non refractory  Poor control; painful, blind 
eye allergies; refused 
surgery;  
74 eyes Lower IOP fewer  
medications 
Mean 40.3mmHg 
Spencer, UK45 CS - prospective Refractory  Uncontrolled IOP: surgery 
refused or unlikely 
58 eyes Reduction in 
glaucoma 
medicines 
Mean 33.0 mmHg 
Martin, UK46 CS - prospective Painful blind eyes Pain 30 eyes IOP reduction; pain Mean 51 mm Hg 
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relief 
Kramp, 
Germany32  
CS - 
retrospective 
109 POAG;  84 sec-
ondary  
Uncontrolled glaucoma 193 eyes IOP 10-22 mmHg  Mean 24.6+/-6.7 
mmHg 
Murphy, UK47 CS - 
retrospective 
Refractory: 46% 
neovascular  
Uncontrolled glaucoma 263 eyes IOP <22 mm Hg or 
> 30% drop in IOP 
Mean 40.7 mmHg 
Lai, Hong 
Kong48  
CS - prospective CACG Medical uncontrolled CACG 13 eyes IOP <21mmHg with 
or without 
medication 
Mean 36.4 +/- 12.6 
mm Hg  
Grueb, 
Switzerland49 
CS - 
retrospective 
POAG, PXEG POAG, PXEG 90 eyes 4-18mmHg or 20% 
reduction 
Mean 21 mmHg (12–
36 mmHg) 
Vernon, UK50 CS - 
retrospective 
Refractory; 19%  
19%  
Poor control 42 eyes IOP<22; reduction 
in medicine 
Mean 31.4mmHg 
Iliev, 
Switzerland51 
CS - 
retrospective 
Advanced, 
refractory: 3% 
POAG; 61% 
neovascular  
Refractory glaucoma 131 eyes IOP 6-21 at last visit Mean IOP 
36.9mmHg  
Raivio, 
Finland52 
CS - 
retrospective 
1/3 PXE; POAG/ 
complex  
Poor control; refractory 
glaucoma 
60 eyes 8-21mmHg IOP  27 ± 11 mmHg 
Frezzoti, Italy53 CS - prospective  Advanced/refractor
y: 36% POAG; 64% 
complicated  
Refractory 124 eyes IOP 5-21; pain relief Mean 29.9 +/- 8.4 
mmHg (17-58 
mmHg) 
Zhekov, UK54 CS - 
retrospective 
Refractory. One 
treatment only.  
45 POAG/PACG 
IOP maintained; visual 
acuity 
87 patients Not defined IOP 39.5mmHg 
 
CS = case series; IOP = intraocular pressure; POAG = primary open angle glaucoma; PXEG = primary exfoliative glaucoma; CACG = chronic 
angle closure glaucoma 
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Table 1B. Transscleral diode laser cyclophotocoagulation treatment studies: outcome of treatment and complications  
 Follow up Outcome: Post op IOP 
Outcome:  
Visual acuity (change) 
Complications  
(n) number of eyes Comments 
Studies in Africa   
Egbert 41 Mean 13.2 
months  
≥20%mmHg drop in 47%; 
48% final IOP <22 mm 
Hg  
Worse in 23% but not 
defined 
Atonic pupil (92) 28%; transient 
hyphaema (3), severe iritis (2). No 
hypotony, phthisis or sympathetic 
ophthalmia. 
 
Mavrakanas 
36 
Variable  At last visit 51% eyes had 
>50% lower IOP 
Not reported No serious complications  
Preussner33 1 year, 26 eyes Mean reduction: 
7.5mmHg 
Not reported No serious complications Medication reduced from 
1.5 to 1.2.  
Schulze34 3 months Mean 35.6mmHg Not reported Atonic pupil (4) 10.6%; transient 
iritis (1) (2.1%) 
Low dose diode used 
Studies in other countries   
Rotchford30 5 years 79.6% controlled at final 
follow up 
≥2 lines: worse 30.6% (15 
eyes): 9 glaucoma 
progression. 
Vitreous haemorrhage (1); retinal 
detachment (1); macula oedema (4) 
 
Ghosh29 24 months Mean 17.2 (12-28);  
84.8% IOP<21mmHg 
>2 lines: same 76.1%; 
worse 23.9%; (11 eyes); 9 
glaucoma progression.  
Macula hole (1); retinal detachment 
(1); macula oedema (2). No 
hypotony.  
 
Kuchar42 Mean 60.3 
days  
22.7 mmHg at last follow-
up, 40.1 % decrease. 
One line of VA: better 
21%; worse 21%.  
Hypotony (1).  
Butt40  12 months Mean 15mmHg at 6 mon; 
14.15mmHg at 1 year 
Not reported Anterior uveitis, cataract (8) 13.3% 
each; hyphaemia (5) 8.3%; hypotony 
(6) 10%  
45% of eyes retreated. 6% 
had three treatments.   
Bloom43  No data Mean 19.3mmHg. 
71% treatment success 
≥2 lines: worse 9% Phthisis(1); chronic hypotony(2); 
hyphaema and vitreous 
haemorrhage (1) 
 
Ansari44 12.5 (4–30) 
months 
Mean: reduced by 45.1% 
to 21.1 mmHg at final 
visit. 
Mean VA preserved in 
those with good VA; 
worse in 13% (glaucoma 
progression; lens opacity, 
Hyphaemia (3); chronic iritis (3); 
corneal oedema (1). No hypotony or 
other serious complications. 
58% reduction in 
medication. All with iritis 
had peripheral iridectomy 
  217 
chronic uveitis) 
Spencer45 Mean 19 (6-
37) months 
Mean 16.7 mm Hg at final 
visit  
>2 lines: worse 32%  Rubeotic eye developed 
endophthalmitis. Chronic hypotony 
(2) no phthisis (8) 13.3% 
Fewer medications: from 
2.4 to 1.4. Up to 5 
treatment sessions 
Martin46 6 months 26 mm Hg. Pain relief in 
73.3%  
Not reported Hypotony (3); phthisis (1); uveitis 
(2); hyphaema (1) 
 
Kramp32 Mean 13.9 (6 
to 48) 
months 
Success 76.4%. Mean 
19.3+/-5.7 mmHg. Best 
results in POAG 
No reported Mild anterior uveitis (31); hyphaema 
(1); phthisis bulbi (3)  
≤6 sessions. 2 phthisical 
eyes had neovascular 
glaucoma and PXG 
Murphy47 17 months (6-
46) 
Mean 17.7 mmHg. 
Reduction of 52.6%. 
Success 89% 
Not reported Hypotony ranged from 0% in POAG 
to 18.8% in uveitic glaucoma. 
Persistent uveitis 1.6%: most in 
complicated glaucoma 
A third of eyes were 
retreated 
Lai48  Mean 26.5 
(+/- 4.2) 
months 
Success 92.3%. Mean 18.7 
+/- 12.2 mm Hg at final 
visit 
≥2 lines: same 15.4%; 
better 46.2%; worse (5 
eyes). 
No hypotony. Atonic pupil (7)  
Grueb49 ≥24 months Mean 16 (9–27) mmHg. 
Success 36.7% all 
40.9% POAG 
Not reported Hyphaema (1); anterior uveitis (10). 
No phthisis. 
 
Vernon50 Mean 65.7 
(36-84) 
months 
88.1% success. 50.3% 
reduction in IOP. Mean 
15.6 +/- 6.3 mmHg 
Same 26.2%  
Better 9.5%  
Worse 64.3%   
Transient hypotony (2) Fewer medications: from 
2.6 to 1.7. ≤6 sessions. 
Focus on maintaining 
acuity 
Iliev51 Mean 30 
months (no 
range)  
Success in 69.5%. 45.8% 
IOP controlled with 1 
treatment 
Not reported Hypotony (23) 17.6%. 74% of these 
eyes had neovascular glaucoma. 
Chronic uveitis (1); severe dry eye 
(1); hyphaema (1) vitreous 
haemorrhage (1). 
Fewer medications: mean 
from 2.97 to 1.39. Multiple 
eyes were retreated.  
Raivio52 26 (3–75) 
months 
18±5mmHg at 6months,  
19±7mmHg at 1year, 
80% had 30% reduction 
in IOP at last follow up 
Not reported Mild anterior uveitis 25%; 
hyphaema (2 eyes), vitreous 
haemorrhage (1). No hypotony. 
 
Frezzoti53 17 (3-42) 
months 
20.8mmHg (range 6-45) 
last visit 
Loss of two or more lines: 
12.9% 
Mild anterior uveitis (3) 2.4%; 
hypaema (2) 1.6%. No hypotony or 
phthisis 
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Zhekov54 3 years 17.8mmHg at 6 weeks 
maintained over 3 years 
Same or better: 83.6% Hypotony 5%; no uveitis  
IOP= intraocular pressure 
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PATIENTS AND METHODS 
Ethical approval was obtained from the ethics committee of the London School of 
Hygiene & Tropical Medicine and from the institutional review board of Abubakar 
Tafawa Balewa University Teaching Hospital (ATBUTH), Bauchi, Nigeria. The study 
adhered to the tenets of the Declaration of Helsinki. 
 
Glaucoma was diagnosed on the basis of vertical cup-disc-ratio (VCDR), IOP and visual 
field analysis, where possible, in patients attending ATBUTH eye clinic. Presenting visual 
acuity (VA) was measured in each eye using a Snellen E chart and categorized using 
World Health Organization definitions. New patients with a range of severity of POAG 
but who had a VA of 3/60 or better in one or both eyes were recruited for primary 
treatment. The following patients were not recruited: previous glaucoma surgery; those 
who were already blind from glaucoma in both eyes (VA of less than 3/60) and those 
who preferred to use topical medication. Given local fears about eye surgery, particularly 
on only seeing eyes, the laser treatment was explained as “computer light treatment”. 
Data are presented on individuals who had a presenting VA of 3/60 or better in the 
treated eye and who were followed up for a minimum of 12 months.  
 
After obtaining written consent, retrobulbar anaesthesia with lignocaine and adrenaline 
2% was administered. Treatment was performed in the operating theatre using the G-
probe of the Iridex diode 810nm laser (IridexCorporation.1212 Terra Bella Avenue 
Mountain View, CA 94043, USA) in continuous mode. The probe heel was placed at the 
edge of the limbus matching the contour of the scleral curvature so that the small 0.7mm 
protrusion indented the sclera approximately 1.2mm posteriorly to optimize energy 
delivery at the site of the ciliary body. Approximately 20 shots were delivered for 
2000ms, titrating the power to just below an audible pop to reduce the risk of 
inflammation and postoperative hyphaema.53 Treatment was given over 360 degrees, 
avoiding the ciliary vessels at the 3 and 9 o’clock positions. A sub-conjunctival injection 
of dexamethasone 2mg was given and the eye padded for an hour. Oral diclofenac 
potassium 50mg was prescribed twice a day and G. dexamethasone 0,1% four times a day 
for one month, tailing off thereafter over a few weeks. On the first post-operative day, 
VA was measured using a Snellen E chart, patients underwent slit-lamp biomicroscopy 
for signs of complications such as inflammation or hyphaema and IOPs were measured 
using Goldmann applanation tonometry.  
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Patients were reviewed at one day, one week and at one, four, six and 12 months after 
treatment when VA and IOPs were measured. Anterior segments were examined at the 
slit lamp for complications at each visit. Patients were given dates to return for follow up 
but were not actively traced. If the IOP was raised (>21mmHg) at follow up topical 
medication was initiated and if the pressure was still high at the next visit TDLC 
retreatment was offered. A second session of laser was given to those who consented. 
 
The outcomes of the study were IOP control, defined as less than 22mmHg, change in 
VA, defined as at least two lines change in Snellen VA, and follow up rates. Absolute 
measures of IOP were used to define control rather than a % reduction given the very 
high IOPs at presentation (72% of eyes were treated when their IOP was >30mmHg and 
40% had IOPs ≥40mmHg). 
Data management 
If both eyes were treated, the first eye was included as the study eye. Data were entered 
into a database created with Epidata and exported into Stata/IC 14.1 statistical software 
(StataCorpLP TX 77845 USA) for descriptive analysis. Follow up, IOP and VA findings at 
baseline and on the first postoperative day, at one week and at one, four, six and 12 
months are presented. 
 
RESULTS 
 
204 seeing eyes with glaucoma which had not previously had surgical or laser treatment 
underwent TDLC. 17 (8.3%) eyes were retreated. The average power setting was 1770mW 
(range 1100-2300mW) with duration of 2000ms. The average number of laser spots 
delivered per eye was 20 (range 15-25).  
 
The mean age of the 204 patients was 52 years (range 12-85 years) and 69% were male. 
The mean vertical cup disc ratio (VCDR) in treated eyes at presentation was 0.9 with 
44% having a VCDR of 1.0. Visual field analysis was only possible in 65 (32%) eyes 
 
Not all patients attended every follow up (Table 2). A total of 107 (52.5%) were followed 
up at 12 months. Rates of follow up were higher in males than females at 12 months (69% 
and 31% respectively) at each follow up visit. Follow up did not differ by age. 
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Table 2: Baseline and post operative IOP and topical medication use after TDLC treatment 
 
 Number followed up IOP (mmHg) 
<22mmHg (eyes 
with IOP data) 
On topical 
medication  
 
Eyes % With IOP data 
Without 
IOP data Mean SD Range N % N % 
Baseline 204 100.0% 202 2 39 11 22-72 0 0% 0 0% 
1 day 199 97.5% 191 8 12 5 2.-30 178 93.2% 1 1% 
1 week 184 90.2% 177 7 11 5 1-28 163 92.1% 5 3% 
1 month 162 79.4% 156 6 15 7 1-48 130 83.3% 16 10% 
4 months 137 67.2% 131 6 18 9 2-50 100 76.3% 16 12% 
6 months 118 57.8% 116 2 19 8 3-52 86 74.1% 14 12% 
12 months 107 52.5% 106 1 19 7 7-45 77 72.6% 11 10% 
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Intraocular pressure  
In some eyes IOP could not be measured at baseline and follow up due to marked 
corneal oedema, pain or poor cooperation. The mean IOP before treatment (202/204 
eyes) was 39mmHg (SD 11mmHg; range 22-72mmHg)(Table 2) and the median was 
37mmHg (interquartile range 29-46mmHg). On the first postoperative day, the mean 
IOP was 12mmHg, being 12, 11, 15, 18, 19 and 19 (range 7-45)mmHg on day one, at one 
week, and 1, 4, 6 and 12 months respectively. At 12 months 72.6% (106/107 eyes with data) 
of treated eyes had an IOP of <22 mmHg. The proportion of eyes on topical glaucoma 
medication at follow up visits ranged from 1% to 11% over the 12 months, being 10% at 12 
months.  
 
Findings were very similar for eyes having only one session of laser treatment (187 eyes), 
with 73.7% (99 eyes) having an IOP of <22mmHg. Mean IOP at 12 months was 19 (range 
7-45) mmHg. 
There was no significant association between final IOP and initial IOP. There was also no 
association between final IOP with laser energy used nor on the number of laser spots 
delivered. There were no age or gender differences in IOP at baseline or at 12 months.  
The mean pre-treatment IOP in those with complete one year follow up (mean: 
37mmHg, range 12-72mmHg) was similar to the total population.  
Visual acuity 
The majority of eyes (83/106 eyes with data), 78%) either retained their baseline VA (70, 
66%) or had improvement by two or more lines (13, 12%). Visual acuity deteriorated by 
two or more lines in 25 eyes (23%): these eyes had a slightly higher IOP before treatment 
(mean 41mmHg, range 26-72) than eyes not losing acuity (mean 37mmHg, range 22-60). 
At 12 months the mean IOP in the eyes that lost vision was 29mmHg (range 8-45) 
compared with 19mmHg (range 7-30) in eyes not losing vision. In addition, 12 (52%) of 
eyes losing vision had a VCDR of 1.0 before treatment compared with 28 (39%) of eyes 
not losing vision. Four eyes losing vision had progression of cataract, and 6 had 
persistent corneal oedema. Visual loss in the remaining eyes was due to glaucoma 
progression.   
Safety and complications 
A few patients had mild anterior uveitis on the first postoperative day, which resolved 
with topical steroid therapy (Table 3). No eyes developed hyphaema or other serious 
complications. Transient hypotony i.e., IOP of <6 mmHg, developed in four eyes during 
follow up but this did not persist at one year.  Eyes which were retreated had slightly 
higher complication rates, with one eye developing severe uveitis. 
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Table 3. Complications after first and second treatment with transscleral diode 
laser cyclophotocoagulation 
 
Complications First treatment  (204 eyes) 
Second treatment       
(17 eyes) 
 N % N % 
Mild anterior uveitis 11 5.9 2 11.8 
Severe uveitis 1 0.5 1 5.9 
Hypotony (<6mmHg) - temporary 4 2.2 0 0 
Hypotony (<6mmHg) - persistent 0 0 0 0 
Corneal oedema 5 2.7 1 5.9 
Cataract progression 4 2.2 0 0 
 
DISCUSSION  
This is the largest case series of TDLC as a primary treatment for seeing glaucomatous 
eyes in Africa. Unlike other studies from Africa the inclusion criteria were clearly defined 
as were the outcomes. A standard treatment protocol was used and all treatments were 
delivered by one ophthalmologist who had undergone TDLC training in the United 
Kingdom. The proportion of patients reaching 12 months of follow up was reasonable. 
TDLC was effective at attaining IOP <22mmHg in a high proportion of treated eyes, the 
majority of whom did not require additional treatment, with good preservation of VA in 
the short term. The findings of the present study need to be considered in the context of 
the patients included (i.e., as an alternative to those who did not accept incisional 
surgery or who consistently did not adhere to topical medication, or where it was 
anticipated that they would not return for regular follow up after surgery). Laser 
treatment was, therefore, offered to patients where it was considered the only viable 
alternative. As in other TDLC studies, immediate post-treatment complications were 
minimal, but were slightly higher in retreated eyes.   
 
There was good acceptance of TDLC treatment, which may be explained by the term 
used to describe it, which avoided the local Hausa term for surgery, “fidar ido”, which 
means “butchering”. The treatment was described as ‘computer light treatment’ 
presented as a once-off, but repeatable treatment, which is desirable in settings where 
there is a fear of surgery and hospitalization, and where there is not a culture of 
attending follow up appointments. For service providers the TDLC procedure is easy to 
learn and the solid-state laser used is cheaper, reliable and more versatile than other 
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lasers. 
 
Poor follow up of patients is a challenge in the delivery of glaucoma care in Africa, as in 
this study, where patients either did not return for follow up at all, or did so at irregular 
intervals. Despite this, in our study over half returned at 12 months which was a marked 
improvement in comparison with previous findings in the same hospital.11 However, poor 
follow up may have biased the findings, since a greater proportion of those who did not 
return may have lost vision and lost faith in healthcare. Having stated this, however, it 
might have been that a greater proportion of patients in whom vision had stabilised or 
improved failed to return, believing that they were ‘cured’. The poor follow up rates 
emphasizes the need in rural Africa for a procedure that maintains IOP, which has few 
postoperative complications and where regular follow up is less critical. The present 
study suggests that follow up at 4 months may be an important time to detect those 
where treatment has failed to adequately control IOP. 
 
Comparison of our findings with other studies from Africa is difficult given the variation 
in study design, indications for and methods of treatment, outcome definitions  and 
follow up rates (Table 1). For example, the study in Ghana was a clinical trial to assess 
different laser power settings. Treatment was offered as a primary treatment and 92 eyes 
were treated: at three months 38 of the 79 patients who attended (48%) had an IOP of 
22mmHg or less; 16 of these eyes had been retreated with laser and topical medication 
was being used in 68 eyes.36 The study in Tanzania was a retrospective review of 179 
treated eyes only 49 of whom had at least one follow up visit. At the 3-6 month follow up 
4/12 eyes had an IOP of 21mmHg or less and 9 eyes were retreated.37 The study in 
Cameroon used a 910nm laser (not the usual 810nm laser) to treat 272 eyes but only 26 
were followed up at 12 months when the average IOP reduction was 7.5 mmHg, this 
being lower than in our study.34 In the Malawi study, a low dose of 900mW (instead of 
the more usual power of approximately 2000mW) was used to treat POAG and 
pseudoexfoliative glaucoma. At 3 months mean IOP had fallen from 38.5mmHg to 
35.6mmHg and in 50% of treated eyes the IOP returned to pre-treatment levels.35 These 
poor outcomes are probably explained by the low power setting used. 
 
Most glaucoma patients of African ancestry lose vision rapidly if they are not treated or 
have poor IOP control.54  In our study the majority of treated eyes either maintained 
their baseline VA or their acuity improved. The latter may be explained by resolution of 
corneal oedema in eyes with very high IOPs.  
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Complications following treatment were minimal in the present study, and compared 
well with other studies on seeing eyes (Table 1). TDLC has had a relatively bad press in 
industrialized countries since it is frequently offered as the treatment of last resort or for 
eyes with complicated, intractable glaucoma. Failure rates and high complications rates 
are much more likely in these eyes which will have had multiple procedures and many 
will have had refractory glaucoma (e.g. secondary to rubeosis etc.)49  than in those where 
it was used as a primary treatment, as in the present study. In the present study, the 
majority of patients whose vision deteriorated suffered the results of age-related 
processes such as cataract progression, or progression of glaucoma in end-stage, elderly 
eyes, rather than as a direct result of the procedure itself. 
 
In the present study the target used to define control was an IOP of <22 mmHg, a target 
used in other studies. However, the natural history and optimal target IOP to control 
glaucoma in Africa is not known. A further limitation of this study was that visual fields, 
vertical cup:disc ratios and other parameters were not used to monitor disease 
progression . There are several reasons for the limitations. Firstly, reliable assessment of 
visual fields is very difficult amongst uneducated African patients, many of whom have 
extensive visual field loss and are not familiar with interacting with technology. Second, 
many patients had corneal oedema at baseline, which precluded baseline optic disc 
imaging, and lastly, optical coherence tomography was not available, which would have 
provided objective data to monitor structural changes at the optic nerve head. However, 
monitoring optic disc change in eyes with very advanced disease would be challenging, 
as in the present study, where almost half the eyes had a cup:disc ratio of 1.0 before 
treatment. The present study had a number of other limitations, including the relatively 
small sample size and limited follow up rates, as discussed above. 
 
The authors suggest that the findings of the present study are generalisable to other 
parts of Africa where challenges faced by most glaucoma patients are similar. A recent 
review of TDLC treatment concluded that this form of treatment is effective at lowering 
IOP and reducing the need for medication. TDLC is a simple, quick, minimally-invasive 
therapy which is worth considering by general ophthalmologists as a primary treatment55 
or as an alternative to surgical interventions in low-income settings. The findings of the 
present study suggest that TDLC could be an alternative primary treatment in an African 
setting. TDLC appeared to be acceptable, provided reasonable IOP control after one 
session and preserved vision at least in the short term, for patients who would otherwise 
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have remained without treatment, and confirmed that TDLC is convenient and well 
tolerated.40 
 
Implications for service delivery / research 
The similarity of the results in the present study with other studies around the world, the 
low cost, acceptability and ease of delivering TDLC laser treatment, offers some promise 
in the otherwise bleak landscape of glaucoma control in Africa. Given that a once-off 
treatment is the desired approach to glaucoma control, clinical trials are needed to 
compare the efficacy, acceptability, cost and safety of other forms of laser treatment as a 
primary treatment for glaucoma. Future studies of glaucoma in Africa need to use 
standard definitions of control together with robust methods to assess disease 
progression in terms of structural and functional parameters, with adequate sample sizes 
to allow for loss to follow up.  
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Chapter 8: Implications of the findings for programmes, 
policy and further research 
The majority of people with glaucoma in Africa only present to eye care facilities when 
they have symptoms of loss of vision in at least one eye, and many patients continue to 
go blind because of poor adherence to medical treatment, poor acceptance of surgery 
and failure to attend for regular follow up. In an attempt to delay blindness, MI was used 
to test the hypothesis that it would increase the uptake of surgery or laser treatment. The 
interview was adapted to the local language and customs to make it more acceptable to 
patients. Although there was an overall increase in acceptance compared with the period 
before the trial, there was no statistically significant difference between the intervention 
and usual care arms of the trial.  
 
There are many possible reasons why MI did not have the desired effect. Firstly, MI may 
not have been delivered well or accepted in the right spirit by participants. The 
counsellors who delivered MI may not have acquired adequate skills as they did not 
undergo formal training. A limitation of the trial was that only one interview could be 
assessed for fidelity using MITI (during pilot testing), and further assessment was not 
possible as all interviews conducted during the trial were in Hausa or Pidgin English 
which the assessors could not understand. The WAI questionnaire did however, show 
that good collaborative relationships developed between interviewers and participants. 
Cultural attitudes and practices are also likely to be relevant. Professional or formal 
counselling only became widespread in Africa as a result of HIV, and may have had 
negative connotations for some. Others were reluctant to open up, seeing MI as 
something foreign and an intrusion into their private lives, as they were required to 
share intimate life experiences or beliefs with a total stranger, who was not even their 
doctor. However, for others it was a novelty, which they were keen to participate in, 
seeing it as an opportunity to be listened to and have their questions answered. In this 
study participants were offered a second session of MI but none returned. These 
individuals were not asked why they did not return which might be because they were 
completely satisfied with one session, or they felt it was not valuable and did not wish to 
repeat it.  
The primary outcome of the trial fails, what is the way forward?  
“An unreasonable yet widespread practice is the labeling of all randomized trials as 
either positive or negative on the basis of whether the p value for the primary outcome is 
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less than 0.05. This view is overly simplistic. P values should be interpreted as a 
continuum wherein the smaller the p value, the greater the strength of the evidence for a 
real treatment effect.” (Pocock et al (N Engl J Med 375(9): page 861[257].  In this paper 
Pocock described 12 questions that should be asked to map the path forward if the 
primary outcome of a clinical trial carried out fails to give a statistically significant result. 
We attempt to answer these questions in relation to this study.  
1. Is There Some Indication of Potential Benefit? 
There is an indication of potential benefit as seen in the overall improvement in uptake 
of surgery as a higher proportion of patients underwent surgery or laser in the 
intervention arm than in the enhanced usual care arm.  
2. Was the Trial Underpowered? 
The sample size of the trial was calculated based on the pilot study where the number 
undergoing treatment was 50% higher in the MIG group than in the control group i.e., 
300, with 150 in each arm of the trial. The sample actually recruited (276 participants) fell 
short of the calculated sample size. If the sample size of 300 had been achieved, the 
difference between the two arms of the trial would still not have been statistically 
significant with the current proportions of participants undergoing surgery or laser (OR 
1.58, p=0.208). 
3. Was the Primary Outcome Appropriate (or Accurately Defined)?  
The primary outcome was appropriately defined and very objective i.e., whether patients 
underwent surgery or laser within 2 months of date given. 
4. Was the Population Appropriate?  
The patient population recruited was appropriate. 
5. Was the Treatment Regimen / Intervention Appropriate?  
There are still questions to answer about the appropriateness of counselling in this 
counselling naïve environment. In the past there has been stigma associated with 
counselling because of HIV/AIDS and also mental illness and addiction. This may have 
made patients defensive or anxious about the intervention. Was MI the right 
intervention to offer? For a location where there were no specialist trained counsellors, 
the literature suggested that this was a counselling technique that could be taught with 
reasonable fidelity to mid cadre workers[205, 258, 259] and could work in ethnic 
communities. Secondly, was the dose of the MI given enough? One treatment session 
only was given in this study because in the pilot study none of the patients offered a 
second session returned. Reasons for this were not explored but the implications are that 
they were either completely satisfied with one session, or they felt that the session was 
either not helpful or not a good use of their resources. The MI sessions varied in length 
                    235 
and this was left up to the interviewer. Thirdly, did the sessions deliver MI of high 
quality? Unfortunately it was not possible to quantify or substantiate whether the 
interviews followed the true MI spirit as it was not possible to carry out fidelity testing to 
assess the quality of interviews. The Working Alliance Inventory test may not have been 
a very objective measure of true collaboration it as it relies on self-report and hence is 
subjective.  Patients and interviewers can as well be nice to each other and rate the 
collaboration very high regardless of what they truly felt. One point to mention is that 
introduction of MI to the clinic may have altered the way staff interacted with all 
patients, with the routine explanation of the disease, its management and prognosis 
being given in a more empathetic manner.  This may have led to greater uptake of 
treatment overall, including in the non-intervention arm. 
6. Were There Deficiencies in Trial Conduct? A true treatment effect may be 
diluted, or disappear entirely, if there is poor adherence to the study protocol. 
The trail was conducted according to the protocol and there were no protocol deviations.  
The possibility of contamination cannot be completely ruled out in this trial even though 
efforts were made to prevent this. For example, interviewers asked patients not to 
discuss whether they had had an interview with staff and other patients but this may 
have been ignored by some patients as all sat in the same waiting area in the clinic. We 
found no practical way to separate the two groups without un-masking project staff. 
7. Is a Claim of Noninferiority of Value?  
No relevant to this trial.  
8. Do Subgroup Findings Elicit Positive Signals?  
Subgroup analysis was not carried out as this was not planned and the sample size was 
not calculated to provide adequate power for subgroup analysis. 
9. Do Secondary Outcomes Reveal Positive Findings?  
There is a plan to carry out secondary outcome analysis, but as follow up is poor it is 
unlikely that this analysis will be adequately powered to give statistically significant 
differences. 
10. Can Alternative Analyses Help?  
Some covariate-adjusted analyses of baseline variables strongly related to the primary 
outcome were undertaken but these did not change the general results, although they 
showed some interesting relationships. 
11. Does More Positive External Evidence Exist?  
There is a body of evidence of the effectiveness of MI for a range of conditions but there 
is no evidence that it is effective in improving adherence to treatment in glaucoma care 
in the few studies carried out.[260-263] 
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12. Is There a Strong Biologic Rationale That favours the Treatment?  
Not relevant to this trial 
 
Improving the Design of Future Trials of MI for glaucoma in Africa 
Future trials of MI for glaucoma could benefit from the lessons learnt in this trial in 
terms of the design and implementation.  
1. Provide formal training in MI for all the interviewers to ensure that they attain high 
levels of competence, and deliver MI in the spirit of compassion, autonomy, 
collaboration and evocation. 
2. Improve fidelity testing of MI interviews, which could be done by someone local 
after formal training. This would mean that fidelity testing could be undertaken on 
transcripts in the local language, which would reduce the risk of loss of insights as a 
result of translation into English. To avoid bias, however, the trained assessor should 
be someone independent of the trial.  
3. Include or use other counselling techniques. There is evidence that MI augmented 
by other counselling techniques seems to give better long lasting outcomes, as it is 
generally believed that MI prepares people for change and to achieve this change 
and maintain it, other interventions, such cognitive behaviour therapy, may be 
needed.[264, 265]  
4. Increase the sample size to allow for loss to follow up and to enable smaller 
differences to be detected, if they exist.  However, a larger sample size would 
increase the logistical challenges and cost. 
5. The study population and the primary outcome could remain the same, as both are 
robust and objective. 
6. Make efforts to prevent or reduce contamination. One way to do this would to 
prevent contact between patients who had MI and those who did not by varying the 
waiting areas in the clinic or the appointments dates. However, this may be 
logistically challenging for a poorly staffed clinic and increases the risk that staff 
would become unmasked to the groups the patients were allocated.  
7. Active follow up would be required, particularly to obtain data on secondary 
outcomes. 
A multicentre trial would increase the generalisability of the findings. 
Second, laser treatment, which was introduced before the trial started, was probably the 
single most important factor responsible for the far higher overall acceptance of 
treatment compared with the period before the laser was available. However, the pilot 
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study, which informed the sample size calculation, was done after laser treatment was 
introduced. The novelty of this new treatment, and the colloquial name given to describe 
it (“computer light”) may have overshadowed any incremental benefit of MI.  
 
The effectiveness of TDLC in our study was similar to studies in many other countries, 
suggesting that TDLC could be an alternative primary treatment for glaucoma: it is 
acceptable to patients many of whom would otherwise be without treatment, gives 
reasonable IOP control after one session with no other treatment, and preserves vision at 
least in the short term. There are also advantages to clinicians, as TDLC is easy to learn, 
deliver and teach, it is safe and quick and can be done as a day case as it is minimally 
invasive, and it can be repeated, if necessary. Running cost are very low after the initial 
outlay, making it affordable to institutions and paying patients.  
 
The findings from this cohort of patients may be generalisable to other parts of Africa 
where the challenges faced by most glaucoma patients and their clinicians are similar. 
General ophthalmologists could consider using TDLC as a primary treatment, 
particularly in rural areas. Other advantages of diode laser are that it is portable and 
versatile as it can be used to treat other eye diseases and so offers promise in the 
otherwise bleak landscape of glaucoma control in Africa.  
 
In an attempt to scale up TDLC the researcher has trained five ophthalmologists in the 
National Eye Centre in Kaduna, Nigeria, which is the major teaching hospital for 
ophthalmology. These ophthalmologists have in their turn trained their residents. The 
feedback so far has been very positive, as the treatment was very acceptable to patients 
many of whom had sustained IOP control for the first time.  
Implications for research in TDLC 
 
Given that a once-off treatment is the desired approach for glaucoma control in Africa, 
clinical trials are needed to compare the efficacy, acceptability, cost and safety of laser 
treatment as a primary treatment. As the drive is for a once off minimally invasive 
procedure that is effective, a clinical trial comparing the effectiveness and safety of TDLC 
against more evidence based laser treatments, such as trabeculoplasty, are 
recommended. High quality trials are of TDLC are needed as most published studies are 
of poor quality, and TDLC is currently seen as treatment of last resort, or only for blind 
painful eyes.  
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Future trials of laser treatment for glaucoma in Africa need to use standard definitions of 
control together with robust methods to assess disease progression in terms of structural 
and functional parameters, with adequate sample sizes to allow for loss to follow up. A 
study design to consider is to randomize by eye, with one eye randomised to TDLC and 
the other to trabeculoplasty. This design is possible with laser treatment, as the 
treatment of one eye has no or negligible impact on the other eye, and has the advantage 
of a smaller sample size, although statistical analysis has to take account of the clustered 
design. Long term follow up will be necessary at regular intervals to assess the long term 
outcome on visual fields and visual acuity. A trial of this nature could also address the 
level of IOP required to halt disease progression in African eyes.  
Implications for service delivery  
 
Multiple interventions and approaches are required to reduce glaucoma blindness, the 
“silent thief of sight”, in Africa. Important elements include increasing awareness using 
locally derived terms so that patients present earlier; improving primary eye care for 
earlier detection and referral; improving the education of glaucoma patients about their 
disease and their role in controlling it; improving the quality, capabilities and efficiency 
of services and the attitudes of staff; ensuring the availability of affordable eye drops and 
teaching patients or their carers how to instill them, and evaluating interventions 
appropriate to Africa to improve adherence to topical medication, acceptance of surgery 
and long term follow up. A priority is to establish a safe and effective of once-off 
treatment which is acceptable and affordable.  
 
Data for the secondary outcomes of the trial are being collected and analysed and will be 
written up for publication.  
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